<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus - Hemmingsen, B - 2016 | Cochrane Library</title> <meta property="og:title" content="Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus - Hemmingsen, B - 2016 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012151.pub2/references?cookiesEnabled" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD012151.pub2" /> <meta name="citation_title" content="Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus" /> <meta name="citation_author" content="Bianca Hemmingsen" /> <meta name="citation_author_institution" content="Herlev University Hospital" /> <meta name="citation_author_email" content="biancahemmingsen@hotmail.com" /> <meta name="citation_author" content="David Peick Sonne" /> <meta name="citation_author_institution" content="Gentofte Hospital, University of Copenhagen" /> <meta name="citation_author" content="Maria‐Inti Metzendorf" /> <meta name="citation_author_institution" content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University D&uuml;sseldorf" /> <meta name="citation_author" content="Bernd Richter" /> <meta name="citation_author_institution" content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University D&uuml;sseldorf" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="10" /> <meta name="citation_doi" content="10.1002/14651858.CD012151.pub2" /> <meta name="citation_date" content="2016" /> <meta name="citation_online_date" content="2016/10/17" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012151.pub2/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012151.pub2/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012151.pub2/pdf/CDSR/CD012151/CD012151.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Benzamides [therapeutic use]; Blood Glucose [analysis]; Cardiovascular Diseases [mortality]; Cyclohexanes [adverse effects, therapeutic use]; Diabetes Mellitus, Type 2 [blood, mortality, *prevention &amp; control]; Fasting [blood]; Hypoglycemic Agents [adverse effects, *therapeutic use]; Insulin [*metabolism]; Insulin Secretion; Metformin [therapeutic use]; Nateglinide; Phenylalanine [adverse effects, analogs &amp; derivatives, therapeutic use]; Randomized Controlled Trials as Topic; Sulfonylurea Compounds [adverse effects, *therapeutic use]" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;&#x26;cookiesEnabled" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581423095000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581423095000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1559916431000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581717708000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581717784000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="dMP9BDfH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012151\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012151\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d\x26cookiesEnabled";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x2526cookiesEnabled";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","ru","za","hr"],languageCode:"en",accessStatus:"not-found",doi:"10.1002/14651858.CD012151.pub2",title:"Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus",firstPublishedDate:"Oct 17, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581423095000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581423095000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=dMP9BDfH&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_cookiesEnabled=&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012151.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012151.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD012151.pub2/references/en?cookiesEnabled" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD012151.pub2/references/es?cookiesEnabled" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012151.pub2%2Freferences%3FcookiesEnabled" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
<li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD012151.PUB2" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD012151.pub2/#" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <span>Read comments on this Review(0)</span> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012151.pub2/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;zh&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh&quot;,&quot;title&quot;:&quot;概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012151.pub2/full"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec1-0006"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/appendices#CD012151-sec1-0012"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/table_n/CD012151StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/table_n/CD012151StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD012151.PUB2"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus </h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD012151-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD012151-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD012151-bbs1-0003">additional references</a></li> <li><a class="jump-to" href="#CD012151-bbs1-0004">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD012151-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">Eriksson 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0001"> <div class="citation-journal">Eriksson JG, Lehtovirta M, Ehrnstrom B, Salmela S, Groop L. <span class="citation-title">Long‐term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance</span>. <span class="citation"> Journal of Internal Medicine </span><span class="pubYear">2006</span>;<span class="volume">259</span>(6):553‐60. [PUBMED: 16704555]<a class="crsref citation-link central-link" data-crsref="4406116" href="" ref="info:x-wiley/crsRef/4406116" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16704555" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+beneficial+effects+of+glipizide+treatment+on+glucose+tolerance+in+subjects+with+impaired+glucose+tolerance+&author=JG+Eriksson&author=M+Lehtovirta&author=B+Ehrnstrom&author=S+Salmela&author=L+Groop&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012151-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">NANSY 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0002"> <div class="citation-other">Lindblad U, Lindberg G, Mansson NO, Ranstam J, Tyrberg M, Jansson S, et al. <span class="citation-title">Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)</span>. Diabetes, Obesity &amp; Metabolism<span class="pubYear">2011</span>; Vol. 13, issue 2:185‐8. [PUBMED: 21199271]<a class="crsref citation-link central-link" data-crsref="4406118" href="" ref="info:x-wiley/crsRef/4406118" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Can+sulphonylurea+addition+to+lifestyle+changes+help+to+delay+diabetes+development+in+subjects+with+impaired+fasting+glucose?+The+Nepi+ANtidiabetes+StudY+(NANSY)+&author=U+Lindblad&author=G+Lindberg&author=NO+Mansson&author=J+Ranstam&author=M+Tyrberg&author=S+Jansson&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0003"> <div class="citation-other">Melander A, Lindblad U, Ranstam J. <span class="citation-title">The NEPI Antidiabetes Study (NANSY), a Scandinavian Complement to the DPP Study</span>. Diabetes<span class="pubYear">1999</span>; Vol. SA351. <a class="crsref citation-link central-link" data-crsref="4406119" href="" ref="info:x-wiley/crsRef/4406119" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+NEPI+Antidiabetes+Study+(NANSY),+a+Scandinavian+Complement+to+the+DPP+Study&author=A+Melander&author=U+Lindblad&author=J+Ranstam&publication_year=1999&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0004"> <div class="citation-journal">Tyrberg M, Melander A, Lovestam‐Adrian M, Lindblad U. <span class="citation-title">Retinopathy in subjects with impaired fasting glucose: the NANSY‐Eye baseline report</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2008</span>;<span class="volume">10</span>(8):646‐51. [PUBMED: 17645554]<a class="crsref citation-link central-link" data-crsref="4406120" href="" ref="info:x-wiley/crsRef/4406120" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17645554" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Retinopathy+in+subjects+with+impaired+fasting+glucose:+the+NANSY%E2%80%90Eye+baseline+report&author=M+Tyrberg&author=A+Melander&author=M+Lovestam%E2%80%90Adrian&author=U+Lindblad&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012151-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">NAVIGATOR 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0011"> <div class="citation-other"><span class="citation-title">Novartis clinical result database ‐ NAVIGATOR</span>. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3223 (accessed 28 April 2016). <a class="crsref citation-link central-link" data-crsref="4406128" href="" ref="info:x-wiley/crsRef/4406128" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0005"> <div class="citation-journal">Bethel MA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, et al. <span class="citation-title">Estimating diabetes risk in patients with impaired glucose tolerance and cardiovascular disease (CVD) or risk factors for CVD</span>. <span class="citation"> Diabetes </span><span class="pubYear">2011</span>;<span class="volume">60</span>(0):A357‐8. <a class="crsref citation-link central-link" data-crsref="4406122" href="" ref="info:x-wiley/crsRef/4406122" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Estimating+diabetes+risk+in+patients+with+impaired+glucose+tolerance+and+cardiovascular+disease+(CVD)+or+risk+factors+for+CVD+&author=MA+Bethel&author=AR+Chacra&author=P+Deedwania&author=GR+Fulcher&author=RR+Holman&author=T+Jenssen&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0006"> <div class="citation-journal">Califf RM, Boolell M, Haffner SM, Bethel M, McMurray J, Duggal A, et al. <span class="citation-title">Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial</span>. <span class="citation"> American Heart Journal </span><span class="pubYear">2008</span>;<span class="volume">156</span>(4):623‐32. [PUBMED: 18946890]<a class="crsref citation-link central-link" data-crsref="4406123" href="" ref="info:x-wiley/crsRef/4406123" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18946890" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevention+of+diabetes+and+cardiovascular+disease+in+patients+with+impaired+glucose+tolerance:+rationale+and+design+of+the+Nateglinide+And+Valsartan+in+Impaired+Glucose+Tolerance+Outcomes+Research+(NAVIGATOR)+Trial+&author=RM+Califf&author=M+Boolell&author=SM+Haffner&author=M+Bethel&author=J+McMurray&author=A+Duggal&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0007"> <div class="citation-journal">Califf RM, Chiang FT, Gaciong Z, Giles TD, Laakso M, Leiter LA, et al. <span class="citation-title">Stroke in people with impaired glucose tolerance</span>. <span class="citation"> Circulation </span><span class="pubYear">2011</span>;<span class="volume">124</span>(21). <a class="crsref citation-link central-link" data-crsref="4406124" href="" ref="info:x-wiley/crsRef/4406124" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Stroke+in+people+with+impaired+glucose+tolerance&author=RM+Califf&author=FT+Chiang&author=Z+Gaciong&author=TD+Giles&author=M+Laakso&author=LA+Leiter&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0008"> <div class="citation-journal">NAVIGATOR Study Group. <span class="citation-title">Effect of nateglinide on the incidence of diabetes and cardiovascular events</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2010</span>;<span class="volume">362</span>(16):1463‐76. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1056/NEJMoa1001122." target="_blank"><span>10.1056/NEJMoa1001122.</span></a>]<a class="crsref citation-link central-link" data-crsref="4406125" href="" ref="info:x-wiley/crsRef/4406125" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20228402" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0009"> <div class="citation-journal">NAVIGATOR Study Group. <span class="citation-title">Effect of valsartan on the incidence of diabetes and cardiovascular events</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2010</span>;<span class="volume">362</span>(16):1477‐90. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1056/NEJMoa1001121" target="_blank"><span>10.1056/NEJMoa1001121</span></a>]<a class="crsref citation-link central-link" data-crsref="4406126" href="" ref="info:x-wiley/crsRef/4406126" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20228403" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0010"> <div class="citation-other">NCT00097786. <span class="citation-title">Long‐term study of nateglinide+valsartan to prevent or delay type II diabetes mellitus and cardiovascular complications (Navigator)</span>. clinicaltrials.gov/ct2/show/NCT00097786 (accessed 22 April 2016). <a class="crsref citation-link central-link" data-crsref="4406127" href="" ref="info:x-wiley/crsRef/4406127" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012151-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">Osei 2004 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0012"> <div class="citation-journal">Osei K, Rhinesmith S, Gaillard T, Schuster D. <span class="citation-title">Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">2004</span>;<span class="volume">53</span>(4):414‐22. [PUBMED: 15045685]<a class="crsref citation-link central-link" data-crsref="4406130" href="" ref="info:x-wiley/crsRef/4406130" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15045685" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Beneficial+metabolic+effects+of+chronic+glipizide+in+obese+African+Americans+with+impaired+glucose+tolerance:+implications+for+primary+prevention+of+type+2+diabetes+&author=K+Osei&author=S+Rhinesmith&author=T+Gaillard&author=D+Schuster&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012151-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">Page 1993 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0013"> <div class="citation-journal">Page RC, Harnden KE, Cook JT, Turner RC. <span class="citation-title">Can life‐styles of subjects with impaired glucose tolerance be changed? A feasibility study</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">1992</span>;<span class="volume">9</span>(6):562‐6. [PUBMED: 1643806]<a class="crsref citation-link central-link" data-crsref="4406132" href="" ref="info:x-wiley/crsRef/4406132" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1643806" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Can+life%E2%80%90styles+of+subjects+with+impaired+glucose+tolerance+be+changed?+A+feasibility+study+&author=RC+Page&author=KE+Harnden&author=JT+Cook&author=RC+Turner&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0014"> <div class="citation-journal">Page RC, Harnden KE, Walravens NK, Onslow C, Sutton P, Levy JC, et al. <span class="citation-title">'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance</span>. <span class="citation"> The Quarterly Journal of Medicine </span><span class="pubYear">1993</span>;<span class="volume">86</span>(3):145‐54. [PUBMED: 8483989]<a class="crsref citation-link central-link" data-crsref="4406133" href="" ref="info:x-wiley/crsRef/4406133" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8483989" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title='Healthy+living'+and+sulphonylurea+therapy+have+different+effects+on+glucose+tolerance+and+risk+factors+for+vascular+disease+in+subjects+with+impaired+glucose+tolerance+&author=RC+Page&author=KE+Harnden&author=NK+Walravens&author=C+Onslow&author=P+Sutton&author=JC+Levy&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012151-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">Papoz 1978 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0015"> <div class="citation-journal">Eschwege E. French Study Group for Diabetes Epidemiology (A.F.E.D.I.A.). <span class="citation-title">Short term effects (2 years) of oral treatment for diabetes in the borderline impairment of oral glucose tolerance test</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1974</span>;<span class="volume">10</span>(363):Abstract 31. <a class="crsref citation-link central-link" data-crsref="4406135" href="" ref="info:x-wiley/crsRef/4406135" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0016"> <div class="citation-journal">Papoz L, Job D, Eschwege E, Aboulker JP, Cubeau J, Pequignot G, et al. <span class="citation-title">Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1978</span>;<span class="volume">15</span>(5):373‐80. [PUBMED: 104897]<a class="crsref citation-link central-link" data-crsref="4406136" href="" ref="info:x-wiley/crsRef/4406136" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/104897" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+oral+hypoglycaemic+drugs+on+glucose+tolerance+and+insulin+secretion+in+borderline+diabetic+patients+&author=L+Papoz&author=D+Job&author=E+Eschwege&author=JP+Aboulker&author=J+Cubeau&author=G+Pequignot&publication_year=1978&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD012151-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD012151-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD012151-bbs1-0003">additional references</a></li> <li><a class="jump-to" href="#CD012151-bbs1-0004">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">Bavirti 2003 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0017"> <div class="citation-journal">Bavirti S, Tayek JA. <span class="citation-title">Low‐dose oral glyburide reduces glucose production rates in patients with impaired fasting glucose</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">2003</span>;<span class="volume">52</span>(4):407‐12. [PUBMED: 12701050]<a class="crsref citation-link central-link" data-crsref="4406138" href="" ref="info:x-wiley/crsRef/4406138" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12701050" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Low%E2%80%90dose+oral+glyburide+reduces+glucose+production+rates+in+patients+with+impaired+fasting+glucose+&author=S+Bavirti&author=JA+Tayek&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">Bitzen 1988 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0018"> <div class="citation-journal">Bitzen PO, Melander A, Schersten B, Wahlin‐Boll E. <span class="citation-title">The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia</span>. <span class="citation"> European Journal of Clinical Pharmacology </span><span class="pubYear">1988</span>;<span class="volume">35</span>(1):31‐7. [PUBMED: 3065086]<a class="crsref citation-link central-link" data-crsref="4406140" href="" ref="info:x-wiley/crsRef/4406140" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3065086" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+influence+of+glipizide+on+early+insulin+release+and+glucose+disposal+before+and+after+dietary+regulation+in+diabetic+patients+with+different+degrees+of+hyperglycaemia+&author=PO+Bitzen&author=A+Melander&author=B+Schersten&author=E+Wahlin%E2%80%90Boll&publication_year=1988&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">Cederholm 1985 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0019"> <div class="citation-journal">Cederholm J. <span class="citation-title">Short‐term treatment of glucose intolerance in middle‐aged subjects by diet, exercise and sulfonylurea</span>. <span class="citation"> Upsala Journal of Medical Sciences </span><span class="pubYear">1985</span>;<span class="volume">90</span>(3):229‐42. [PUBMED: 4095819]<a class="crsref citation-link central-link" data-crsref="4406142" href="" ref="info:x-wiley/crsRef/4406142" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/4095819" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Short%E2%80%90term+treatment+of+glucose+intolerance+in+middle%E2%80%90aged+subjects+by+diet,+exercise+and+sulfonylurea+&author=J+Cederholm&publication_year=1985&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">Cederholm 1986 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0020"> <div class="citation-journal">Cederholm J, Wibell L. <span class="citation-title">The impact of treatment on insulin release and relative peripheral resistance during the oral glucose tolerance test. A study of noninsulin‐dependent diabetes mellitus and glucose intolerance</span>. <span class="citation"> Diabete &amp; Metabolisme </span><span class="pubYear">1986</span>;<span class="volume">12</span>(1):10‐5. [PUBMED: 3516748]<a class="crsref citation-link central-link" data-crsref="4406144" href="" ref="info:x-wiley/crsRef/4406144" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3516748" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+impact+of+treatment+on+insulin+release+and+relative+peripheral+resistance+during+the+oral+glucose+tolerance+test.+A+study+of+noninsulin%E2%80%90dependent+diabetes+mellitus+and+glucose+intolerance+&author=J+Cederholm&author=L+Wibell&publication_year=1986&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">DIANA 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0021"> <div class="citation-journal">Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K, et al. <span class="citation-title">Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early‐stage diabetic patients</span>. <span class="citation"> Circulation Journal </span><span class="pubYear">2012</span>;<span class="volume">76</span>(3):712‐20. [PUBMED: 22240597]<a class="crsref citation-link central-link" data-crsref="4406146" href="" ref="info:x-wiley/crsRef/4406146" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22240597" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+voglibose+and+nateglinide+on+glycemic+status+and+coronary+atherosclerosis+in+early%E2%80%90stage+diabetic+patients+&author=Y+Kataoka&author=S+Yasuda&author=Y+Miyamoto&author=K+Sase&author=M+Kosuge&author=K+Kimura&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">Gudipaty 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0022"> <div class="citation-journal">Gudipaty L, Fuller C, Rosenfeld N, Rickels MR. <span class="citation-title">No effect of exenatide or sitagliptin therapy on beta‐cell secretory capacity in early type 2 diabetes</span>. <span class="citation"> Diabetes </span><span class="pubYear">2013</span>;<span class="volume">62</span>:A288. <a class="crsref citation-link central-link" data-crsref="4406148" href="" ref="info:x-wiley/crsRef/4406148" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=No+effect+of+exenatide+or+sitagliptin+therapy+on+beta%E2%80%90cell+secretory+capacity+in+early+type+2+diabetes+&author=L+Gudipaty&author=C+Fuller&author=N+Rosenfeld&author=MR+Rickels&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0023"> <div class="citation-journal">Gudipaty L, Rosenfeld NK, Fuller CS, Gallop R, Schutta MH, Rickels MR. <span class="citation-title">Effect of exenatide, sitagliptin, or glimepiride on beta‐cell secretory capacity in early type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(9):2451‐8. [PUBMED: 24969577]<a class="crsref citation-link central-link" data-crsref="4406149" href="" ref="info:x-wiley/crsRef/4406149" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24969577" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+exenatide,+sitagliptin,+or+glimepiride+on+beta%E2%80%90cell+secretory+capacity+in+early+type+2+diabetes+&author=L+Gudipaty&author=NK+Rosenfeld&author=CS+Fuller&author=R+Gallop&author=MH+Schutta&author=MR+Rickels&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0024"> <div class="citation-other">NCT00775684. <span class="citation-title">Effect of exenatide, sitagliptin or glimepiride on functional ß‐cell mass</span>. clinicaltrials.gov/ct2/show/NCT00775684 (accessed 3 March 2016). <a class="crsref citation-link central-link" data-crsref="4406150" href="" ref="info:x-wiley/crsRef/4406150" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">Hirose 2002 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0025"> <div class="citation-journal">Hirose T, Mizuno R, Yoshimoto T. <span class="citation-title">The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects</span>. <span class="citation"> Endocrine Journal </span><span class="pubYear">2002</span>;<span class="volume">49</span>(6):649‐52. [PUBMED: 12625415]<a class="crsref citation-link central-link" data-crsref="4406152" href="" ref="info:x-wiley/crsRef/4406152" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12625415" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effects+of+nateglinide+following+oral+glucose+load+in+impaired+glucose+tolerance+subjects:+rapid+insulin+stimulation+by+nateglinide+in+IGT+subjects+&author=T+Hirose&author=R+Mizuno&author=T+Yoshimoto&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">Igata 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0026"> <div class="citation-journal">Igata S, Tahara N, Tahara A, Nitta Y, Honda A, Kodama N, et al. <span class="citation-title">Visceral fat metabolic activity is independently associated with coronary artery inflammation in patients with impaired glucose intolerance or type 2 diabetes</span>. <span class="citation"> Circulation </span><span class="pubYear">2014</span>;<span class="volume">130</span>. <a class="crsref citation-link central-link" data-crsref="4406154" href="" ref="info:x-wiley/crsRef/4406154" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Visceral+fat+metabolic+activity+is+independently+associated+with+coronary+artery+inflammation+in+patients+with+impaired+glucose+intolerance+or+type+2+diabetes+&author=S+Igata&author=N+Tahara&author=A+Tahara&author=Y+Nitta&author=A+Honda&author=N+Kodama&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0028"> <div class="citation-journal">Kodama N. <span class="citation-title">Effects of pioglitazone versus glimepiride on abdominal fat glucose metabolism in patients with impaired glucose tolerance and/or type 2 diabetes mellitus</span>. <span class="citation"> Circulation </span><span class="pubYear">2012</span>;<span class="volume">126</span>(21). <a class="crsref citation-link central-link" data-crsref="4406156" href="" ref="info:x-wiley/crsRef/4406156" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22992321" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+pioglitazone+versus+glimepiride+on+abdominal+fat+glucose+metabolism+in+patients+with+impaired+glucose+tolerance+and/or+type+2+diabetes+mellitus+&author=N+Kodama&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0027"> <div class="citation-journal">Kodama N, Tahara N, Tahara A, Honda A, Nitta Y, Mizoguchi M, et al. <span class="citation-title">Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus</span>. <span class="citation"> Journal of Clinical Endocrinology and Metabolism </span><span class="pubYear">2013</span>;<span class="volume">98</span>(11):4438‐45. [PUBMED: 24030946]<a class="crsref citation-link central-link" data-crsref="4406155" href="" ref="info:x-wiley/crsRef/4406155" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24030946" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+pioglitazone+on+visceral+fat+metabolic+activity+in+impaired+glucose+tolerance+or+type+2+diabetes+mellitus+&author=N+Kodama&author=N+Tahara&author=A+Tahara&author=A+Honda&author=Y+Nitta&author=M+Mizoguchi&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0029"> <div class="citation-journal">Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. <span class="citation-title">Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator‐controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta</span>. <span class="citation"> JACC. Cardiovascular Imaging </span><span class="pubYear">2011</span>;<span class="volume">4</span>(10):1110‐8. [PUBMED: 21999871]<a class="crsref citation-link central-link" data-crsref="4406157" href="" ref="info:x-wiley/crsRef/4406157" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21999871" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+attenuates+atherosclerotic+plaque+inflammation+in+patients+with+impaired+glucose+tolerance+or+diabetes+a+prospective,+randomized,+comparator%E2%80%90controlled+study+using+serial+FDG+PET/CT+imaging+study+of+carotid+artery+and+ascending+aorta+&author=M+Mizoguchi&author=N+Tahara&author=A+Tahara&author=Y+Nitta&author=N+Kodama&author=T+Oba&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0030"> <div class="citation-other">NCT00722631. <span class="citation-title">Anti‐inflammatory effects of pioglitazone</span>. clinicaltrials.gov/ct2/show/NCT00722631 (accessed 22 April 2016). <a class="crsref citation-link central-link" data-crsref="4406158" href="" ref="info:x-wiley/crsRef/4406158" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0031"> <div class="citation-other">Nitta Y, Tahara N, Honda A, Tahara A, Kodama N, Mizoguchi M, et al. <span class="citation-title">Effects of pioglitazone on coronary arterial inflammation evaluated by serial FDG‐PET/CT in patients with impaired glucose tolerant or type 2 diabetes</span>. Circulation. Conference: American Heart Association. <span class="pubYear">2012</span>; Vol. 126, issue 21. <a class="crsref citation-link central-link" data-crsref="4406159" href="" ref="info:x-wiley/crsRef/4406159" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+pioglitazone+on+coronary+arterial+inflammation+evaluated+by+serial+FDG%E2%80%90PET/CT+in+patients+with+impaired+glucose+tolerant+or+type+2+diabetes+&author=Y+Nitta&author=N+Tahara&author=A+Honda&author=A+Tahara&author=N+Kodama&author=M+Mizoguchi&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0032"> <div class="citation-journal">Nitta Y, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, et al. <span class="citation-title">Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG‐PET/CT imaging</span>. <span class="citation"> JACC. Cardiovascular Imaging </span><span class="pubYear">2013</span>;<span class="volume">6</span>(11):1172‐82. [PUBMED: 24229770]<a class="crsref citation-link central-link" data-crsref="4406160" href="" ref="info:x-wiley/crsRef/4406160" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24229770" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+decreases+coronary+artery+inflammation+in+impaired+glucose+tolerance+and+diabetes+mellitus:+evaluation+by+FDG%E2%80%90PET/CT+imaging+&author=Y+Nitta&author=N+Tahara&author=A+Tahara&author=A+Honda&author=N+Kodama&author=M+Mizoguchi&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0033"> <div class="citation-journal">Tahara N, Yamagishi S, Mizoguchi M, Tahara A, Imaizumi T. <span class="citation-title">Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes</span>. <span class="citation"> Rejuvenation Research </span><span class="pubYear">2013</span>;<span class="volume">16</span>(5):344‐51. [PUBMED: 23777507]<a class="crsref citation-link central-link" data-crsref="4406161" href="" ref="info:x-wiley/crsRef/4406161" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23777507" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+decreases+asymmetric+dimethylarginine+levels+in+patients+with+impaired+glucose+tolerance+or+type+2+diabetes+&author=N+Tahara&author=S+Yamagishi&author=M+Mizoguchi&author=A+Tahara&author=T+Imaizumi&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">Inoue 1997 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0034"> <div class="citation-journal">Inoue I, Takahashi K, Noji S, Awata T, Negishi K, Katayama S. <span class="citation-title">Acarbose controls postprandial hyperproinsulinemia in non‐insulin dependent diabetes mellitus</span>. <span class="citation"> Diabetes Research and Clinical Practice </span><span class="pubYear">1997</span>;<span class="volume">36</span>(3):143‐51. [PUBMED: 9237780]<a class="crsref citation-link central-link" data-crsref="4406163" href="" ref="info:x-wiley/crsRef/4406163" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9237780" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Acarbose+controls+postprandial+hyperproinsulinemia+in+non%E2%80%90insulin+dependent+diabetes+mellitus+&author=I+Inoue&author=K+Takahashi&author=S+Noji&author=T+Awata&author=K+Negishi&author=S+Katayama&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">Johanson 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0035"> <div class="citation-journal">Johanson EH, Jansson PA, Gustafson B, Sandqvist M, Taskinen MR, Smith U, et al. <span class="citation-title">No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes</span>. <span class="citation"> Diabetes/Metabolism Research and Reviews </span><span class="pubYear">2005</span>;<span class="volume">21</span>(4):376‐81. [PUBMED: 15724236]<a class="crsref citation-link central-link" data-crsref="4406165" href="" ref="info:x-wiley/crsRef/4406165" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=No+acute+effect+of+nateglinide+on+postprandial+lipid+and+lipoprotein+responses+in+subjects+at+risk+for+type+2+diabetes+&author=EH+Johanson&author=PA+Jansson&author=B+Gustafson&author=M+Sandqvist&author=MR+Taskinen&author=U+Smith&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">Katahira 2005 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0036"> <div class="citation-journal">Katahira H, Ishida H. <span class="citation-title">[Effects of mitiglinide in treatment of impaired glucose tolerance]</span>. <span class="citation"> Nihon Rinsho. Japanese Journal of Clinical Medicine </span><span class="pubYear">2005</span>;<span class="volume">63 Suppl 2</span>:444‐50. [PUBMED: 15779420]<a class="crsref citation-link central-link" data-crsref="4406167" href="" ref="info:x-wiley/crsRef/4406167" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15779420" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=[Effects+of+mitiglinide+in+treatment+of+impaired+glucose+tolerance]&author=H+Katahira&author=H+Ishida&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">Lindblad 2001 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0037"> <div class="citation-journal">Lindblad U, Lindwall K, Sjostrand A, Ranstam J, Melander A. <span class="citation-title">The NEPI antidiabetes study (NANSY). 1: short‐term dose‐effect relations of glimepiride in subjects with impaired fasting glucose</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2001</span>;<span class="volume">3</span>(6):443‐51. [PUBMED: 11903417]<a class="crsref citation-link central-link" data-crsref="4406169" href="" ref="info:x-wiley/crsRef/4406169" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11903417" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+NEPI+antidiabetes+study+(NANSY).+1:+short%E2%80%90term+dose%E2%80%90effect+relations+of+glimepiride+in+subjects+with+impaired+fasting+glucose+&author=U+Lindblad&author=K+Lindwall&author=A+Sjostrand&author=J+Ranstam&author=A+Melander&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">Major‐Pedersen 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0038"> <div class="citation-journal">Major‐Pedersen A, Ihlemann N, Hermann TS, Christiansen B, Kveiborg B, Dominguez H, et al. <span class="citation-title">Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose‐load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?</span>. <span class="citation"> Hormone and Metabolic Research </span><span class="pubYear">2008</span>;<span class="volume">40</span>(9):607‐13. [PUBMED: 18792871]<a class="crsref citation-link central-link" data-crsref="4406171" href="" ref="info:x-wiley/crsRef/4406171" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18792871" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+acute+and+chronic+attenuation+of+postprandial+hyperglycemia+on+postglucose%E2%80%90load+endothelial+function+in+insulin+resistant+individuals:+is+stimulation+of+first+phase+insulin+secretion+beneficial+for+the+endothelial+function?+&author=A+Major%E2%80%90Pedersen&author=N+Ihlemann&author=TS+Hermann&author=B+Christiansen&author=B+Kveiborg&author=H+Dominguez&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0039"> <div class="citation-other">NCT00259168. <span class="citation-title">Insulin resistance and vessel function after meals: does early intervention make a difference?</span>. clinicaltrials.gov/ct2/show/NCT00259168?term=NCT00259168&amp;rank=1 (accessed 22 April 2016). <a class="crsref citation-link central-link" data-crsref="4406172" href="" ref="info:x-wiley/crsRef/4406172" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">NCT00744965 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0040"> <div class="citation-other">NCT00744965. <span class="citation-title">Treatment of mild gestational diabetes with glyburide versus placebo</span>. clinicaltrials.gov/ct2/show/NCT00744965 (accessed 17 May 2016). <a class="crsref citation-link central-link" data-crsref="4406174" href="" ref="info:x-wiley/crsRef/4406174" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">NCT01563120 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0041"> <div class="citation-other">NCT01563120. <span class="citation-title">A comparison between two oral hypoglycemics ‐ metformin and glybenclamide for the treatment of gestational diabetes mellitus</span>. clinicaltrials.gov/show/NCT01563120 (accessed 17 March 2016). <a class="crsref citation-link central-link" data-crsref="4406176" href="" ref="info:x-wiley/crsRef/4406176" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">Pontiroli 1991 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0042"> <div class="citation-journal">Pontiroli AE, Perfetti MG, Pozza G. <span class="citation-title">Acute effect of glipizide on glucose tolerance in obesity and diabetes mellitus (NIDDM)</span>. <span class="citation"> European Journal of Clinical Pharmacology </span><span class="pubYear">1991</span>;<span class="volume">40</span>(1):23‐6. [PUBMED: 2060541]<a class="crsref citation-link central-link" data-crsref="4406178" href="" ref="info:x-wiley/crsRef/4406178" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2060541" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Acute+effect+of+glipizide+on+glucose+tolerance+in+obesity+and+diabetes+mellitus+(NIDDM)&author=AE+Pontiroli&author=MG+Perfetti&author=G+Pozza&publication_year=1991&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0043"> <div class="citation-journal">Pontiroli AE, Perfetti MG, Pozza G. <span class="citation-title">Improvement of glucose tolerance by minimal doses of glipizide in obese subjects with different degrees of glucose intolerance</span>. <span class="citation"> Hormone and Metabolic Research. Supplement Series </span><span class="pubYear">1992</span>;<span class="volume">26</span>:32‐4. [PUBMED: 1490690]<a class="crsref citation-link central-link" data-crsref="4406179" href="" ref="info:x-wiley/crsRef/4406179" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/1490690" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improvement+of+glucose+tolerance+by+minimal+doses+of+glipizide+in+obese+subjects+with+different+degrees+of+glucose+intolerance+&author=AE+Pontiroli&author=MG+Perfetti&author=G+Pozza&publication_year=1992&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">Ratzmann 1981 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0044"> <div class="citation-journal">Ratzmann KP, Witt S, Schulz B, Jahr D, Heinke P. <span class="citation-title">[Effect of glibenclamide therapy on carbohydrate and lipid metabolism and insulin secretion in patients with glucose tolerance disorders : a 5‐year study]</span> [Einfluss einer Glibenclamid‐Therapie auf Kohlenhydrat‐ und Fettstoffwechsel sowie Insulinsekretion bei Personen mit gestörter Glukosetorleranz: Verlaufsbeobachtungen bis zu 5 Jahren]. <span class="citation"> Zeitschrift fur die Gesamte Innere Medizin und ihre Grenzgebiete </span><span class="pubYear">1981</span>;<span class="volume">36</span>(23):913‐7. [PUBMED: 6805141]<a class="crsref citation-link central-link" data-crsref="4406181" href="" ref="info:x-wiley/crsRef/4406181" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6805141" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=[Effect+of+glibenclamide+therapy+on+carbohydrate+and+lipid+metabolism+and+insulin+secretion+in+patients+with+glucose+tolerance+disorders+:+a+5%E2%80%90year+study]+&author=KP+Ratzmann&author=S+Witt&author=B+Schulz&author=D+Jahr&author=P+Heinke&publication_year=1981&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Ratzmann 1983 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0045"> <div class="citation-journal">Ratzmann KP, Witt S, Schulz B. <span class="citation-title">The effect of long‐term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance</span>. <span class="citation"> Diabète &amp; Métabolisme </span><span class="pubYear">1983</span>;<span class="volume">9</span>(2):87‐93. [PUBMED: 6413265]<a class="crsref citation-link central-link" data-crsref="4406183" href="" ref="info:x-wiley/crsRef/4406183" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6413265" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+long%E2%80%90term+glibenclamide+treatment+on+glucose+tolerance,+insulin+secretion+and+serum+lipids+in+subjects+with+impaired+glucose+tolerance+&author=KP+Ratzmann&author=S+Witt&author=B+Schulz&publication_year=1983&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">Saloranta 2002 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0046"> <div class="citation-journal">Saloranta C, Guitard C, Pecher E, Pablos‐Velasco P, Lahti K, Brunel P, et al. <span class="citation-title">Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2002</span>;<span class="volume">25</span>(12):2141‐6. [PUBMED: 12453951]<a class="crsref citation-link central-link" data-crsref="4406185" href="" ref="info:x-wiley/crsRef/4406185" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12453951" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Nateglinide+improves+early+insulin+secretion+and+controls+postprandial+glucose+excursions+in+a+prediabetic+population+&author=C+Saloranta&author=C+Guitard&author=E+Pecher&author=P+Pablos%E2%80%90Velasco&author=K+Lahti&author=P+Brunel&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">Schmoelzer 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0047"> <div class="citation-journal">Schmoelzer I, Wascher TC. <span class="citation-title">Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance</span>. <span class="citation"> Cardiovascular Diabetology </span><span class="pubYear">2006</span>;<span class="volume">5</span>:9. [PUBMED: 16606452]<a class="crsref citation-link central-link" data-crsref="4406187" href="" ref="info:x-wiley/crsRef/4406187" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16606452" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+repaglinide+on+endothelial+dysfunction+during+a+glucose+tolerance+test+in+subjects+with+impaired+glucose+tolerance+&author=I+Schmoelzer&author=TC+Wascher&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012151-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">The Fasting Hyperglycaemia Study 1997a {published data only} </h4> </div> <div class="bibliography-section" id="CD012151-bib-0048"> <div class="citation-journal">Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC. <span class="citation-title">The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy‐living advice in subjects with increased but not diabetic fasting plasma glucose</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">1997</span>;<span class="volume">46</span>(12 Suppl 1):50‐5. [PUBMED: 9439560]<a class="crsref citation-link central-link" data-crsref="4406189" href="" ref="info:x-wiley/crsRef/4406189" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9439560" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Fasting+Hyperglycaemia+Study:+II.+Randomized+controlled+trial+of+reinforced+healthy%E2%80%90living+advice+in+subjects+with+increased+but+not+diabetic+fasting+plasma+glucose+&author=PA+Dyson&author=MS+Hammersley&author=RJ+Morris&author=RR+Holman&author=RC+Turner&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0049"> <div class="citation-journal">Hammersley MS, Meyer LC, Morris RJ, Manley SE, Turner RC, Holman RR. <span class="citation-title">The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non‐insulin‐dependent diabetes prevention trial</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">1997</span>;<span class="volume">46</span>(12 Suppl 1):44‐9. [PUBMED: 9439559]<a class="crsref citation-link central-link" data-crsref="4406190" href="" ref="info:x-wiley/crsRef/4406190" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9439559" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Fasting+Hyperglycaemia+Study:+I.+Subject+identification+and+recruitment+for+a+non%E2%80%90insulin%E2%80%90dependent+diabetes+prevention+trial+&author=MS+Hammersley&author=LC+Meyer&author=RJ+Morris&author=SE+Manley&author=RC+Turner&author=RR+Holman&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012151-bib-0050"> <div class="citation-journal">Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR. <span class="citation-title">The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">1997</span>;<span class="volume">46</span>(12 Suppl 1):56‐60. [PUBMED: 9439561]<a class="crsref citation-link central-link" data-crsref="4406191" href="" ref="info:x-wiley/crsRef/4406191" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9439561" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Fasting+Hyperglycaemia+Study:+III.+Randomized+controlled+trial+of+sulfonylurea+therapy+in+subjects+with+increased+but+not+diabetic+fasting+plasma+glucose+&author=S+Karunakaran&author=MS+Hammersley&author=RJ+Morris&author=RC+Turner&author=RR+Holman&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD012151-bbs1-0003"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD012151-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD012151-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD012151-bbs1-0004">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">Abdul‐Ghani 2006</h4> </div> <div class="bibliography-section" id="CD012151-bib-0051"> <div class="citation-journal">Abdul‐Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. <span class="citation-title">Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study</span>. <span class="citation"> Diabetes </span><span class="pubYear">2006</span>;<span class="volume">55</span>(5):1430‐5. [PUBMED: 16644701] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16644701" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Insulin+secretion+and+action+in+subjects+with+impaired+fasting+glucose+and+impaired+glucose+tolerance:+results+from+the+Veterans+Administration+Genetic+Epidemiology+Study+&author=MA+Abdul%E2%80%90Ghani&author=CP+Jenkinson&author=DK+Richardson&author=D+Tripathy&author=RA+DeFronzo&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">ACT NOW 2011</h4> </div> <div class="bibliography-section" id="CD012151-bib-0052"> <div class="citation-journal">DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. <span class="citation-title">Pioglitazone for diabetes prevention in impaired glucose tolerance</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2011</span>;<span class="volume">364</span>(12):1104‐15. [PUBMED: 21428766] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21428766" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+for+diabetes+prevention+in+impaired+glucose+tolerance&author=RA+DeFronzo&author=D+Tripathy&author=DC+Schwenke&author=M+Banerji&author=GA+Bray&author=TA+Buchanan&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">ADA 1997</h4> </div> <div class="bibliography-section" id="CD012151-bib-0053"> <div class="citation-journal">The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. <span class="citation-title">Report of the expert committee on the diagnosis and classification of diabetes mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1997</span>;<span class="volume">20</span>(7):1183‐97. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9203460" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">ADA 2003</h4> </div> <div class="bibliography-section" id="CD012151-bib-0054"> <div class="citation-journal">Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. <span class="citation-title">Report of the expert committee on the diagnosis and classification of diabetes mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2003</span>;<span class="volume">26</span>(Suppl 1):S5‐20. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12502614" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">ADA 2008</h4> </div> <div class="bibliography-section" id="CD012151-bib-0055"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Standards of medical care in diabetes ‐ 2008</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>(Suppl 1):S12‐54. [PUBMED: 18165335] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18165335" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">ADA 2010</h4> </div> <div class="bibliography-section" id="CD012151-bib-0056"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Diagnosis and classification of diabetes mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2010</span>;<span class="volume">33</span>(Suppl 1):S62‐9. [PUBMED: 20042775] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20042775" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">ADA 2015</h4> </div> <div class="bibliography-section" id="CD012151-bib-0057"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Standards of medical care in diabetes‐2015</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2015</span>;<span class="volume">38</span>(Suppl 1):S1‐93. [PUBMED: 24357209] <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">ADOPT 2006</h4> </div> <div class="bibliography-section" id="CD012151-bib-0058"> <div class="citation-journal">Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. <span class="citation-title">Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2006</span>;<span class="volume">355</span>(23):2427‐43. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17145742" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glycemic+durability+of+rosiglitazone,+metformin,+or+glyburide+monotherapy&author=SE+Kahn&author=SM+Haffner&author=MA+Heise&author=WH+Herman&author=RR+Holman&author=NP+Jones&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">Anderson 2005</h4> </div> <div class="bibliography-section" id="CD012151-bib-0059"> <div class="citation-journal">Anderson DC. <span class="citation-title">Pharmacologic prevention or delay of type 2 diabetes mellitus</span>. <span class="citation"> Annals of Pharmacotherapy </span><span class="pubYear">2005</span>;<span class="volume">39</span>(1):102‐9. [PUBMED: 15562143] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15562143" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pharmacologic+prevention+or+delay+of+type+2+diabetes+mellitus&author=DC+Anderson&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">Bedford 1982</h4> </div> <div class="bibliography-section" id="CD012151-bib-0060"> <div class="citation-journal">Keen H, Jarrett RJ, McCartney P. <span class="citation-title">The ten‐year follow‐up of the Bedford survey (1962‐1972): glucose tolerance and diabetes</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1982</span>;<span class="volume">22</span>(2):73‐8. [PUBMED: 7060852] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7060852" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+ten%E2%80%90year+follow%E2%80%90up+of+the+Bedford+survey+(1962%E2%80%901972):+glucose+tolerance+and+diabetes&author=H+Keen&author=RJ+Jarrett&author=P+McCartney&publication_year=1982&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">Bell 2013</h4> </div> <div class="bibliography-section" id="CD012151-bib-0061"> <div class="citation-journal">Bell ML, McKenzie JE. <span class="citation-title">Designing psycho‐oncology randomised trials and cluster randomised trials: variance components and intra‐cluster correlation of commonly used psychosocial measures</span>. <span class="citation"> Psycho‐oncology </span><span class="pubYear">2013</span>;<span class="volume">22</span>:1738‐47. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23080401" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Designing+psycho%E2%80%90oncology+randomised+trials+and+cluster+randomised+trials:+variance+components+and+intra%E2%80%90cluster+correlation+of+commonly+used+psychosocial+measures+&author=ML+Bell&author=JE+McKenzie&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">Beller 2013</h4> </div> <div class="bibliography-section" id="CD012151-bib-0062"> <div class="citation-journal">Beller EM, Chen JK, Wang UL, Glasziou PP. <span class="citation-title">Are systematic reviews up‐to‐date at the time of publication?</span>. <span class="citation"> Systematic Reviews </span><span class="pubYear">2013</span>;<span class="volume">2</span>:36. [2046‐4053: (Electronic)] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23714302" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Are+systematic+reviews+up%E2%80%90to%E2%80%90date+at+the+time+of+publication?&author=EM+Beller&author=JK+Chen&author=UL+Wang&author=PP+Glasziou&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">Bhardwaj 2010</h4> </div> <div class="bibliography-section" id="CD012151-bib-0063"> <div class="citation-other">Bhardwaj A, Agarwal V, Phung OJ, Baker WL, Tongbram V, Coleman CI. <span class="citation-title">Can oral hypoglycemic agents restore normoglycemia in individuals with insulin resistance?</span>. Diabetes. Conference: 70th Scientific Sessions of the American Diabetes Association Orlando, FL United States. <span class="pubYear">2010</span>; Vol. 0, issue 0. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Can+oral+hypoglycemic+agents+restore+normoglycemia+in+individuals+with+insulin+resistance?&author=A+Bhardwaj&author=V+Agarwal&author=OJ+Phung&author=WL+Baker&author=V+Tongbram&author=CI+Coleman&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">Black 2007</h4> </div> <div class="bibliography-section" id="CD012151-bib-0064"> <div class="citation-journal">Black C, Donnelly P, McIntyre L, Royle P, Shepherd JJ, Thomas S. <span class="citation-title">Meglitinide analogues for type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2007</span>, Issue 2. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD004654.pub2" target="_blank"><span>10.1002/14651858.CD004654.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Meglitinide+analogues+for+type+2+diabetes+mellitus&author=C+Black&author=P+Donnelly&author=L+McIntyre&author=P+Royle&author=JJ+Shepherd&author=S+Thomas&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">Blickle 2006</h4> </div> <div class="bibliography-section" id="CD012151-bib-0065"> <div class="citation-journal">Blickle JF. <span class="citation-title">Meglitinide analogues: a review of clinical data focused on recent trials</span>. <span class="citation"> Diabetes &amp; Metabolism </span><span class="pubYear">2006</span>;<span class="volume">32</span>(2):113‐20. [PUBMED: 16735959] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16735959" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Meglitinide+analogues:+a+review+of+clinical+data+focused+on+recent+trials&author=JF+Blickle&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">Botnia Study 1996</h4> </div> <div class="bibliography-section" id="CD012151-bib-0066"> <div class="citation-journal">Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, Nissen M, et al. <span class="citation-title">Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex‐specific parental effects</span>. <span class="citation"> Diabetes </span><span class="pubYear">1996</span>;<span class="volume">45</span>(11):1585‐93. [PUBMED: 8866565] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8866565" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metabolic+consequences+of+a+family+history+of+NIDDM+(the+Botnia+study):+evidence+for+sex%E2%80%90specific+parental+effects+&author=L+Groop&author=C+Forsblom&author=M+Lehtovirta&author=T+Tuomi&author=S+Karanko&author=M+Nissen&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">Boutron 2014</h4> </div> <div class="bibliography-section" id="CD012151-bib-0067"> <div class="citation-journal">Boutron I, Altman DG, Hopewell S, Vera‐Badillo F, Tannock I, Ravaud P. <span class="citation-title">Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial</span>. <span class="citation"> Journal of Clinical Oncology </span><span class="pubYear">2014</span>;<span class="volume">32</span>:4120‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25403215" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+spin+in+the+abstracts+of+articles+reporting+results+of+randomized+controlled+trials+in+the+field+of+cancer:+the+SPIIN+randomized+controlled+trial+&author=I+Boutron&author=DG+Altman&author=S+Hopewell&author=F+Vera%E2%80%90Badillo&author=I+Tannock&author=P+Ravaud&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">Brok 2009</h4> </div> <div class="bibliography-section" id="CD012151-bib-0068"> <div class="citation-journal">Brok J, Thorlund K, Wetterslev J, Gluud C. <span class="citation-title">Apparently conclusive meta‐analyses may be inconclusive ‐ Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses</span>. <span class="citation"> International Journal of Epidemiology </span><span class="pubYear">2009</span>;<span class="volume">38</span>(1):287‐98. [PUBMED: 18824466] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18824466" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Apparently+conclusive+meta%E2%80%90analyses+may+be+inconclusive+%E2%80%90+Trial+sequential+analysis+adjustment+of+random+error+risk+due+to+repetitive+testing+of+accumulating+data+in+apparently+conclusive+neonatal+meta%E2%80%90analyses+&author=J+Brok&author=K+Thorlund&author=J+Wetterslev&author=C+Gluud&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">CDC 2015</h4> </div> <div class="bibliography-section" id="CD012151-bib-0069"> <div class="citation-other">Centers for Disease Control and Prevention. <span class="citation-title">2014 National Diabetes Statistics Report</span>. www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html (accessed 15 October 2015). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">Cheng 2006</h4> </div> <div class="bibliography-section" id="CD012151-bib-0070"> <div class="citation-journal">Cheng C, Kushner H, Falkner BE. <span class="citation-title">The utility of fasting glucose for detection of prediabetes</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">2006</span>;<span class="volume">55</span>(4):434‐8. [PUBMED: 16546472] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16546472" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+utility+of+fasting+glucose+for+detection+of+prediabetes&author=C+Cheng&author=H+Kushner&author=BE+Falkner&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">ClinicalTrials.gov</h4> </div> <div class="bibliography-section" id="CD012151-bib-0071"> <div class="citation-other">clinicaltrials.gov/ct2/results?term=prediabetes+drugs&amp;Search=Search (accessed 12 February 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">Corbett 2014</h4> </div> <div class="bibliography-section" id="CD012151-bib-0072"> <div class="citation-journal">Corbett MS, Higgins JP, Woolacott NF. <span class="citation-title">Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool</span>. <span class="citation"> Research Synthesis Methods </span><span class="pubYear">2014</span>;<span class="volume">5</span>:79‐85. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26054027" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Assessing+baseline+imbalance+in+randomised+trials:+implications+for+the+Cochrane+risk+of+bias+tool+&author=MS+Corbett&author=JP+Higgins&author=NF+Woolacott&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">Deeks 2003</h4> </div> <div class="bibliography-section" id="CD012151-bib-0073"> <div class="citation-journal">Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. <span class="citation-title">Evaluating non‐randomised intervention studies</span>. <span class="citation"> Health Technology Assessment (Winchester, England) </span><span class="pubYear">2003</span>;<span class="volume">7</span>(27):iii‐x, 1‐173. [PUBMED: 14499048] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/14499048" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Evaluating+non%E2%80%90randomised+intervention+studies&author=JJ+Deeks&author=J+Dinnes&author=R+D'Amico&author=AJ+Sowden&author=C+Sakarovitch&author=F+Song&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">DeFronzo 1989</h4> </div> <div class="bibliography-section" id="CD012151-bib-0074"> <div class="citation-journal">DeFronzo RA, Ferrannini E, Simonson DC. <span class="citation-title">Fasting hyperglycemia in non‐insulin‐dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">1989</span>;<span class="volume">38</span>(4):387‐95. [PUBMED: 2657323] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2657323" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Fasting+hyperglycemia+in+non%E2%80%90insulin%E2%80%90dependent+diabetes+mellitus:+contributions+of+excessive+hepatic+glucose+production+and+impaired+tissue+glucose+uptake+&author=RA+DeFronzo&author=E+Ferrannini&author=DC+Simonson&publication_year=1989&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">Diabetes Prevention Program 2002</h4> </div> <div class="bibliography-section" id="CD012151-bib-0075"> <div class="citation-journal">Knowler WC, Barrett‐Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. <span class="citation-title">Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2002</span>;<span class="volume">346</span>(6):393‐403. [PUBMED: 11832527] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11832527" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Reduction+in+the+incidence+of+type+2+diabetes+with+lifestyle+intervention+or+metformin&author=WC+Knowler&author=E+Barrett%E2%80%90Connor&author=SE+Fowler&author=RF+Hamman&author=JM+Lachin&author=EA+Walker&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">Diabetes Prevention Program FU 2009</h4> </div> <div class="bibliography-section" id="CD012151-bib-0076"> <div class="citation-journal">Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. <span class="citation-title">10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study</span>. <span class="citation"> Lancet </span><span class="pubYear">2009</span>;<span class="volume">374</span>(9702):1677‐86. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1016/S0140-6736(09)61457-4" target="_blank"><span>10.1016/S0140‐6736(09)61457‐4</span></a>; PUBMED: 19878986] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19878986" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=10%E2%80%90year+follow%E2%80%90up+of+diabetes+incidence+and+weight+loss+in+the+Diabetes+Prevention+Program+Outcomes+Study+&author=WC+Knowler&author=SE+Fowler&author=RF+Hamman&author=CA+Christophi&author=HJ+Hoffman&author=AT+Brenneman&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">diabetes.co.uk 2016a</h4> </div> <div class="bibliography-section" id="CD012151-bib-0077"> <div class="citation-other">Diabetes.co.uk. <span class="citation-title">Convert whole blood results to plasma readings</span>. www.diabetes.co.uk/whole‐blood‐readings‐to‐plasma‐converter.html (assessed 22 August 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">diabetes.co.uk 2016b</h4> </div> <div class="bibliography-section" id="CD012151-bib-0078"> <div class="citation-other">Diabetes.co.uk. <span class="citation-title">Blood sugar converter</span>. www.diabetes.co.uk/blood‐sugar‐converter.html (assessed 22 August 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0056"> <div class="reference-title-banner"> <h4 class="title">DREAM 2008</h4> </div> <div class="bibliography-section" id="CD012151-bib-0079"> <div class="citation-journal">DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, et al. <span class="citation-title">Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>(5):1007‐14. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.2337/dc07-1868%3C/body%3E%3C/html%3E" target="_blank"><span>10.2337/dc07‐1868&lt;/body&gt;&lt;/html&gt;</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18268075" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+ramipril+and+rosiglitazone+on+cardiovascular+and+renal+outcomes+in+people+with+impaired+glucose+tolerance+or+impaired+fasting+glucose:+results+of+the+Diabetes+REduction+Assessment+with+ramipril+and+rosiglitazone+Medication+(DREAM)+trial+&author=GR+Dagenais&author=HC+Gerstein&author=R+Holman&author=A+Budaj&author=A+Escalante&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0057"> <div class="reference-title-banner"> <h4 class="title">Drugs.com 2016a</h4> </div> <div class="bibliography-section" id="CD012151-bib-0080"> <div class="citation-other">Drugs.com. <span class="citation-title">Glimepiride</span>. www.drugs.com/pro/glimepiride.html (accessed 5 October 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0058"> <div class="reference-title-banner"> <h4 class="title">Drugs.com 2016b</h4> </div> <div class="bibliography-section" id="CD012151-bib-0081"> <div class="citation-other">Drugs.com. <span class="citation-title">Gliclazide 80 mg tablets</span>. www.drugs.com/uk/gliclazide‐80‐mg‐tablets‐leaflet.html (accessed 5 October 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0059"> <div class="reference-title-banner"> <h4 class="title">Dunkley 2014</h4> </div> <div class="bibliography-section" id="CD012151-bib-0082"> <div class="citation-journal">Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, et al. <span class="citation-title">Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta‐analysis</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(4):922‐33. [PUBMED: 24652723] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24652723" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetes+prevention+in+the+real+world:+effectiveness+of+pragmatic+lifestyle+interventions+for+the+prevention+of+type+2+diabetes+and+of+the+impact+of+adherence+to+guideline+recommendations:+a+systematic+review+and+meta%E2%80%90analysis+&author=AJ+Dunkley&author=DH+Bodicoat&author=CJ+Greaves&author=C+Russell&author=T+Yates&author=MJ+Davies&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0060"> <div class="reference-title-banner"> <h4 class="title">Egbewale 2014</h4> </div> <div class="bibliography-section" id="CD012151-bib-0083"> <div class="citation-journal">Egbewale BE, Lewis M, Sim J. <span class="citation-title">Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study</span>. <span class="citation"> BMC Medical Research Methodology </span><span class="pubYear">2014</span>;<span class="volume">14</span>:49. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1186/1471-2288-14-49" target="_blank"><span>10.1186/1471‐2288‐14‐49</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24712304" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Bias,+precision+and+statistical+power+of+analysis+of+covariance+in+the+analysis+of+randomized+trials+with+baseline+imbalance:+a+simulation+study+&author=BE+Egbewale&author=M+Lewis&author=J+Sim&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0061"> <div class="reference-title-banner"> <h4 class="title">Finnish Diabetes Prevention Study Group 2001</h4> </div> <div class="bibliography-section" id="CD012151-bib-0084"> <div class="citation-journal">Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne‐Parikka P, et al. <span class="citation-title">Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2001</span>;<span class="volume">344</span>(18):1343‐50. [PUBMED: 11333990] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11333990" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevention+of+type+2+diabetes+mellitus+by+changes+in+lifestyle+among+subjects+with+impaired+glucose+tolerance+&author=J+Tuomilehto&author=J+Lindstrom&author=JG+Eriksson&author=TT+Valle&author=H+Hamalainen&author=P+Ilanne%E2%80%90Parikka&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0062"> <div class="reference-title-banner"> <h4 class="title">Gosmanov 2014</h4> </div> <div class="bibliography-section" id="CD012151-bib-0085"> <div class="citation-journal">Gosmanov AR, Wan J. <span class="citation-title">Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice</span>. <span class="citation"> American Journal of the Medical Sciences </span><span class="pubYear">2014</span>;<span class="volume">348</span>(3):191‐4. [PUBMED: 24556928] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24556928" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Low+positive+predictive+value+of+hemoglobin+A1c+for+diagnosis+of+prediabetes+in+clinical+practice+&author=AR+Gosmanov&author=J+Wan&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0063"> <div class="reference-title-banner"> <h4 class="title">GRADEproGDT 2015 [Computer program]</h4> </div> <div class="bibliography-section" id="CD012151-bib-0086"> <div class="citation-other">GRADE Working Group, McMaster University. <span class="citation-title">GRADEproGDT</span>. Hamilton (ON): GRADE Working Group, McMaster University, <span class="pubYear">2015</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0064"> <div class="reference-title-banner"> <h4 class="title">Harrower 2000</h4> </div> <div class="bibliography-section" id="CD012151-bib-0087"> <div class="citation-journal">Harrower AD. <span class="citation-title">Comparative tolerability of sulphonylureas in diabetes mellitus</span>. <span class="citation"> Drug Safety </span><span class="pubYear">2000</span>;<span class="volume">22</span>(4):313‐20. [PUBMED: 10789825] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/10789825" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparative+tolerability+of+sulphonylureas+in+diabetes+mellitus&author=AD+Harrower&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0065"> <div class="reference-title-banner"> <h4 class="title">Hemmingsen 2016a</h4> </div> <div class="bibliography-section" id="CD012151-bib-0088"> <div class="citation-journal">Hemmingsen B, Krogh J, Metzendorf MI, Richter B. <span class="citation-title">Dipeptidyl‐peptidase (DPP)‐4 inhibitors or glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2016</span>, Issue 5. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD012204" target="_blank"><span>10.1002/14651858.CD012204</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dipeptidyl%E2%80%90peptidase+(DPP)%E2%80%904+inhibitors+or+glucagon%E2%80%90like+peptide+(GLP)%E2%80%901+analogues+for+prevention+or+delay+of+type+2+diabetes+mellitus+and+its+associated+complications+in+persons+at+increased+risk+for+the+development+of+type+2+diabetes+mellitus+&author=B+Hemmingsen&author=J+Krogh&author=MI+Metzendorf&author=B+Richter&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0066"> <div class="reference-title-banner"> <h4 class="title">Hemmingsen 2016b</h4> </div> <div class="bibliography-section" id="CD012151-bib-0089"> <div class="citation-journal">Hemmingsen B, Krogh J, Metzendorf MI, Richter B. <span class="citation-title">Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2016</span>, Issue 4. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD012106.pub2" target="_blank"><span>10.1002/14651858.CD012106.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sodium%E2%80%90glucose+cotransporter+(SGLT)+2+inhibitors+for+prevention+or+delay+of+type+2+diabetes+mellitus+and+its+associated+complications+in+people+at+risk+for+the+development+of+type+2+diabetes+mellitus+&author=B+Hemmingsen&author=J+Krogh&author=MI+Metzendorf&author=B+Richter&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0067"> <div class="reference-title-banner"> <h4 class="title">Higgins 2002</h4> </div> <div class="bibliography-section" id="CD012151-bib-0090"> <div class="citation-journal">Higgins JPT, Thompson SG. <span class="citation-title">Quantifying heterogeneity in a meta‐analysis</span>. <span class="citation"> Statistics in Medicine </span><span class="pubYear">2002</span>;<span class="volume">21</span>:1539‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12111919" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Quantifying+heterogeneity+in+a+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0068"> <div class="reference-title-banner"> <h4 class="title">Higgins 2003</h4> </div> <div class="bibliography-section" id="CD012151-bib-0091"> <div class="citation-journal">Higgins JPT, Thompson SG, Deeks JJ, Altman DG. <span class="citation-title">Measuring inconsistency in meta‐analysis</span>. <span class="citation"> BMJ </span><span class="pubYear">2003</span>;<span class="volume">327</span>(7414):557‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12958120" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Measuring+inconsistency+in+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&author=JJ+Deeks&author=DG+Altman&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0069"> <div class="reference-title-banner"> <h4 class="title">Higgins 2009</h4> </div> <div class="bibliography-section" id="CD012151-bib-0092"> <div class="citation-journal">Higgins JPT, Thompson SG, Spiegelhalter DJ. <span class="citation-title">A re‐evaluation of random‐effects meta‐analysis</span>. <span class="citation"> Journal of the Royal Statistical Society: Series A (Statistics in Society) </span><span class="pubYear">2009</span>;<span class="volume">172</span>(1):137‐59. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+re%E2%80%90evaluation+of+random%E2%80%90effects+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&author=DJ+Spiegelhalter&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0070"> <div class="reference-title-banner"> <h4 class="title">Higgins 2010</h4> </div> <div class="bibliography-section" id="CD012151-bib-0093"> <div class="citation-journal">Higgins JP, Whitehead A, Simmonds M. <span class="citation-title">Sequential methods for random‐effects meta‐analysis</span>. <span class="citation"> Statistics in Medicine </span><span class="pubYear">2011</span>;<span class="volume">30</span>(9):903‐21. [PUBMED: 21190240] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21472757" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sequential+methods+for+random%E2%80%90effects+meta%E2%80%90analysis&author=JP+Higgins&author=A+Whitehead&author=M+Simmonds&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0071"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011a</h4> </div> <div class="bibliography-section" id="CD012151-bib-0094"> <div class="citation-other">Higgins JPT, Green S, editor(s). <span class="citation-title">Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0072"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011b</h4> </div> <div class="bibliography-section" id="CD012151-bib-0095"> <div class="citation-journal">Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. <span class="citation-title">The Cochrane Collaboration's tool for assessing risk of bias in randomised trials</span>. <span class="citation"> BMJ </span><span class="pubYear">2011</span>;<span class="volume">343</span>:d5928. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22008217" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Cochrane+Collaboration's+tool+for+assessing+risk+of+bias+in+randomised+trials&author=JPT+Higgins&author=DG+Altman&author=PC+Gøtzsche&author=P+Jüni&author=D+Moher&author=AD+Oxman&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0073"> <div class="reference-title-banner"> <h4 class="title">Hopper 2011</h4> </div> <div class="bibliography-section" id="CD012151-bib-0096"> <div class="citation-journal">Hopper I, Billah B, Skiba M, Krum H. <span class="citation-title">Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta‐analysis of randomised controlled clinical trials</span>. <span class="citation"> European Journal of Cardiovascular Prevention and Rehabilitation </span><span class="pubYear">2011</span>;<span class="volume">18</span>(6):813‐23. [PUBMED: 21878448] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21878448" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevention+of+diabetes+and+reduction+in+major+cardiovascular+events+in+studies+of+subjects+with+prediabetes:+meta%E2%80%90analysis+of+randomised+controlled+clinical+trials+&author=I+Hopper&author=B+Billah&author=M+Skiba&author=H+Krum&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0074"> <div class="reference-title-banner"> <h4 class="title">Hróbjartsson 2013</h4> </div> <div class="bibliography-section" id="CD012151-bib-0097"> <div class="citation-journal">Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. <span class="citation-title">Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors</span>. <span class="citation"> Canadian Medical Association Journal </span><span class="pubYear">2013</span>;<span class="volume">185</span>(4):E201‐11. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23359047" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observer+bias+in+randomized+clinical+trials+with+measurement+scale+outcomes:+a+systematic+review+of+trials+with+both+blinded+and+nonblinded+assessors+&author=A+Hr%C3%B3bjartsson&author=AS+Thomsen&author=F+Emanuelsson&author=B+Tendal&author=J+Hilden&author=I+Boutron&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0075"> <div class="reference-title-banner"> <h4 class="title">ICH 1997</h4> </div> <div class="bibliography-section" id="CD012151-bib-0098"> <div class="citation-other">International Conference on Harmonisation Expert Working Group. <span class="citation-title">International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice //1997 CFR &amp; ICH Guidelines</span>. PA 19063‐2043. <span class="pubYear">USA: Barnett International/PAREXEL, 1997</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0076"> <div class="reference-title-banner"> <h4 class="title">IDF 2013</h4> </div> <div class="bibliography-section" id="CD012151-bib-0099"> <div class="citation-book">International Diabetes Federation. <span class="citation">IDF Diabetes Atlas</span>. 6th Edition. Brussels: International Diabetes Federation, <span class="pubYear">2013</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0077"> <div class="reference-title-banner"> <h4 class="title">IEC 2009</h4> </div> <div class="bibliography-section" id="CD012151-bib-0100"> <div class="citation-journal">International Expert Committee. <span class="citation-title">International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(7):1327‐34. [PUBMED: 19502545] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19502545" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0078"> <div class="reference-title-banner"> <h4 class="title">Jensen 2002</h4> </div> <div class="bibliography-section" id="CD012151-bib-0101"> <div class="citation-journal">Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. <span class="citation-title">Beta‐cell function is a major contributor to oral glucose tolerance in high‐risk relatives of four ethnic groups in the U.S</span>. <span class="citation"> Diabetes </span><span class="pubYear">2002</span>;<span class="volume">51</span>(7):2170‐8. [PUBMED: 12086947] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12086947" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Beta%E2%80%90cell+function+is+a+major+contributor+to+oral+glucose+tolerance+in+high%E2%80%90risk+relatives+of+four+ethnic+groups+in+the+U.S+&author=CC+Jensen&author=M+Cnop&author=RL+Hull&author=WY+Fujimoto&author=SE+Kahn&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0079"> <div class="reference-title-banner"> <h4 class="title">Kirkham 2010</h4> </div> <div class="bibliography-section" id="CD012151-bib-0102"> <div class="citation-journal">Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. <span class="citation-title">The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews</span>. <span class="citation"> BMJ </span><span class="pubYear">2010</span>;<span class="volume">340</span>:c365. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1136/bmj.c365" target="_blank"><span>10.1136/bmj.c365</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20156912" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+impact+of+outcome+reporting+bias+in+randomised+controlled+trials+on+a+cohort+of+systematic+reviews+&author=JJ+Kirkham&author=KM+Dwan&author=DG+Altman&author=C+Gamble&author=S+Dodd&author=R+Smyth&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0080"> <div class="reference-title-banner"> <h4 class="title">Lan 1983</h4> </div> <div class="bibliography-section" id="CD012151-bib-0103"> <div class="citation-journal">Lan KKG, DeMets DL. <span class="citation-title">Discrete sequential boundaries for clinical trials</span>. <span class="citation"> Biometrika </span><span class="pubYear">1983</span>;<span class="volume">70</span>:659‐63. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Discrete+sequential+boundaries+for+clinical+trials&author=KKG+Lan&author=DL+DeMets&publication_year=1983&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0081"> <div class="reference-title-banner"> <h4 class="title">Liberati 2009</h4> </div> <div class="bibliography-section" id="CD012151-bib-0104"> <div class="citation-journal">Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. <span class="citation-title">The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration</span>. <span class="citation"> PLoS Medicine </span><span class="pubYear">2009</span>;<span class="volume">6</span>(7):1‐28. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1371/journal.pmed.1000100" target="_blank"><span>10.1371/journal.pmed.1000100</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+PRISMA+statement+for+reporting+systematic+and+meta%E2%80%90analyses+of+studies+that+evaluate+interventions:+explanation+and+elaboration+&author=A+Liberati&author=DG+Altman&author=J+Tetzlaff&author=C+Mulrow&author=PC+G%C3%B8tzsche&author=JPA+Ioannidis&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0082"> <div class="reference-title-banner"> <h4 class="title">Lundh 2012</h4> </div> <div class="bibliography-section" id="CD012151-bib-0105"> <div class="citation-journal">Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. <span class="citation-title">Industry sponsorship and research outcome</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2012</span>, Issue 12. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.MR000033.pub2" target="_blank"><span>10.1002/14651858.MR000033.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23235689" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Industry+sponsorship+and+research+outcome&author=A+Lundh&author=S+Sismondo&author=J+Lexchin&author=OA+Busuioc&author=L+Bero&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0083"> <div class="reference-title-banner"> <h4 class="title">Mathieu 2009</h4> </div> <div class="bibliography-section" id="CD012151-bib-0106"> <div class="citation-journal">Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. <span class="citation-title">Comparison of registered and published primary outcomes in randomized controlled trials</span>. <span class="citation"> JAMA </span><span class="pubYear">2009</span>;<span class="volume">302</span>:977‐84. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19724045" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+registered+and+published+primary+outcomes+in+randomized+controlled+trials&author=S+Mathieu&author=I+Boutron&author=D+Moher&author=DG+Altman&author=P+Ravaud&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0084"> <div class="reference-title-banner"> <h4 class="title">McCall 2001</h4> </div> <div class="bibliography-section" id="CD012151-bib-0107"> <div class="citation-journal">McCall AL. <span class="citation-title">Clinical review of glimepiride</span>. <span class="citation"> Expert Opinion on Pharmacotherapy </span><span class="pubYear">2001</span>;<span class="volume">2</span>(4):699‐713. [PUBMED: 11336617] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11336617" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+review+of+glimepiride&author=AL+McCall&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0085"> <div class="reference-title-banner"> <h4 class="title">Meader 2014</h4> </div> <div class="bibliography-section" id="CD012151-bib-0108"> <div class="citation-journal">Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. <span class="citation-title">A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation</span>. <span class="citation"> Systematic Reviews </span><span class="pubYear">2014</span>;<span class="volume">3</span>:82. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25056145" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+checklist+designed+to+aid+consistency+and+reproducibility+of+GRADE+assessments:+development+and+pilot+validation+&author=N+Meader&author=K+King&author=A+Llewellyn&author=G+Norman&author=J+Brown&author=M+Rodgers&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0086"> <div class="reference-title-banner"> <h4 class="title">Meigs 2002</h4> </div> <div class="bibliography-section" id="CD012151-bib-0109"> <div class="citation-journal">Meigs JB, Nathan DM, D'Agostino RB, Wilson PW. <span class="citation-title">Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2002</span>;<span class="volume">25</span>(10):1845‐50. [PUBMED: 12351489] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12351489" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Fasting+and+postchallenge+glycemia+and+cardiovascular+disease+risk:+the+Framingham+Offspring+Study+&author=JB+Meigs&author=DM+Nathan&author=RB+D'Agostino&author=PW+Wilson&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0087"> <div class="reference-title-banner"> <h4 class="title">Morris 2013</h4> </div> <div class="bibliography-section" id="CD012151-bib-0110"> <div class="citation-journal">Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, et al. <span class="citation-title">Progression rates from HbA1c 6.0‐6.4% and other prediabetes definitions to type 2 diabetes: a meta‐analysis</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2013</span>;<span class="volume">56</span>(7):1489‐93. [PUBMED: 23584433] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23584433" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Progression+rates+from+HbA1c+6.0%E2%80%906.4%+and+other+prediabetes+definitions+to+type+2+diabetes:+a+meta%E2%80%90analysis+&author=DH+Morris&author=K+Khunti&author=F+Achana&author=B+Srinivasan&author=LJ+Gray&author=MJ+Davies&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0088"> <div class="reference-title-banner"> <h4 class="title">NDDG 1979</h4> </div> <div class="bibliography-section" id="CD012151-bib-0111"> <div class="citation-journal">National Diabetes Data Group. <span class="citation-title">Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group</span>. <span class="citation"> Diabetes </span><span class="pubYear">1979</span>;<span class="volume">28</span>(12):1039‐57. [PUBMED: 510803] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/510803" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0089"> <div class="reference-title-banner"> <h4 class="title">Pantalone 2012</h4> </div> <div class="bibliography-section" id="CD012151-bib-0112"> <div class="citation-journal">Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. <span class="citation-title">Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2012</span>;<span class="volume">14</span>(9):803‐9. [PUBMED: 22486923] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22486923" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Increase+in+overall+mortality+risk+in+patients+with+type+2+diabetes+receiving+glipizide,+glyburide+or+glimepiride+monotherapy+versus+metformin:+a+retrospective+analysis+&author=KM+Pantalone&author=MW+Kattan&author=C+Yu&author=BJ+Wells&author=S+Arrigain&author=A+Jain&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0090"> <div class="reference-title-banner"> <h4 class="title">Phillippe 2013</h4> </div> <div class="bibliography-section" id="CD012151-bib-0113"> <div class="citation-journal">Phillippe HM, Wargo KA. <span class="citation-title">Mitiglinide for type 2 diabetes treatment</span>. <span class="citation"> Expert Opinion on Pharmacotherapy </span><span class="pubYear">2013</span>;<span class="volume">14</span>(15):2133‐44. [PUBMED: 23992284] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23992284" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Mitiglinide+for+type+2+diabetes+treatment&author=HM+Phillippe&author=KA+Wargo&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0091"> <div class="reference-title-banner"> <h4 class="title">Phung 2012</h4> </div> <div class="bibliography-section" id="CD012151-bib-0114"> <div class="citation-journal">Phung OJ, Baker WL, Tongbram V, Bhardwaj A, Coleman CI. <span class="citation-title">Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta‐analysis</span>. <span class="citation"> Annals of Pharmacotherapy </span><span class="pubYear">2012</span>;<span class="volume">46</span>(4):469‐76. [PUBMED: 22474136] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22474136" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Oral+antidiabetic+drugs+and+regression+from+prediabetes+to+normoglycemia:+a+meta%E2%80%90analysis&author=OJ+Phung&author=WL+Baker&author=V+Tongbram&author=A+Bhardwaj&author=CI+Coleman&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0092"> <div class="reference-title-banner"> <h4 class="title">Pogue 1997</h4> </div> <div class="bibliography-section" id="CD012151-bib-0115"> <div class="citation-journal">Pogue JM, Yusuf S. <span class="citation-title">Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis</span>. <span class="citation"> Controlled Clinical Trials </span><span class="pubYear">1997</span>;<span class="volume">18</span>(6):580‐93; discussion 661‐6. [PUBMED: 9408720] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9408720" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cumulating+evidence+from+randomized+trials:+utilizing+sequential+monitoring+boundaries+for+cumulative+meta%E2%80%90analysis+&author=JM+Pogue&author=S+Yusuf&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0093"> <div class="reference-title-banner"> <h4 class="title">RevMan 2014 [Computer program]</h4> </div> <div class="bibliography-section" id="CD012151-bib-0116"> <div class="citation-other">The Nordic Cochrane Centre, The Cochrane Collaboration. <span class="citation-title">Review Manager (RevMan)</span>. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, <span class="pubYear">2014</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0094"> <div class="reference-title-banner"> <h4 class="title">Riley 2011</h4> </div> <div class="bibliography-section" id="CD012151-bib-0117"> <div class="citation-journal">Riley RD, Higgins JP, Deeks JJ. <span class="citation-title">Interpretation of random effects meta‐analyses</span>. <span class="citation"> BMJ </span><span class="pubYear">2011</span>;<span class="volume">342</span>:d549. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21310794" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Interpretation+of+random+effects+meta%E2%80%90analyses&author=RD+Riley&author=JP+Higgins&author=JJ+Deeks&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0095"> <div class="reference-title-banner"> <h4 class="title">Riley 2013</h4> </div> <div class="bibliography-section" id="CD012151-bib-0118"> <div class="citation-journal">Riley RD, Kauser I, Bland M, Thijs L, Staessen JA, Wang J, et al. <span class="citation-title">Meta‐analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data</span>. <span class="citation"> Statistics in Medicine </span><span class="pubYear">2013</span>;<span class="volume">32</span>(16):2747‐66. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23303608" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Meta%E2%80%90analysis+of+randomised+trials+with+a+continuous+outcome+according+to+baseline+imbalance+and+availability+of+individual+participant+data+&author=RD+Riley&author=I+Kauser&author=M+Bland&author=L+Thijs&author=JA+Staessen&author=J+Wang&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0096"> <div class="reference-title-banner"> <h4 class="title">Roumie 2012</h4> </div> <div class="bibliography-section" id="CD012151-bib-0119"> <div class="citation-journal">Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al. <span class="citation-title">Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study</span>. <span class="citation"> Annals of Internal Medicine </span><span class="pubYear">2012</span>;<span class="volume">157</span>(9):601‐10. [PUBMED: 23128859] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23128859" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparative+effectiveness+of+sulfonylurea+and+metformin+monotherapy+on+cardiovascular+events+in+type+2+diabetes+mellitus:+a+cohort+study+&author=CL+Roumie&author=AM+Hung&author=RA+Greevy&author=CG+Grijalva&author=X+Liu&author=HJ+Murff&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0097"> <div class="reference-title-banner"> <h4 class="title">Sartor 1980</h4> </div> <div class="bibliography-section" id="CD012151-bib-0120"> <div class="citation-journal">Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. <span class="citation-title">Ten‐year follow‐up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation</span>. <span class="citation"> Diabetes </span><span class="pubYear">1980</span>;<span class="volume">29</span>(1):41‐9. [PUBMED: 7380107] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7380107" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ten%E2%80%90year+follow%E2%80%90up+of+subjects+with+impaired+glucose+tolerance:+prevention+of+diabetes+by+tolbutamide+and+diet+regulation+&author=G+Sartor&author=B+Schersten&author=S+Carlstrom&author=A+Melander&author=A+Norden&author=G+Persson&publication_year=1980&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0098"> <div class="reference-title-banner"> <h4 class="title">Schramm 2011</h4> </div> <div class="bibliography-section" id="CD012151-bib-0121"> <div class="citation-journal">Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. <span class="citation-title">Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study</span>. <span class="citation"> European Heart Journal </span><span class="pubYear">2011</span>;<span class="volume">32</span>(15):1900‐8. [PUBMED: 21471135] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21471135" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Mortality+and+cardiovascular+risk+associated+with+different+insulin+secretagogues+compared+with+metformin+in+type+2+diabetes,+with+or+without+a+previous+myocardial+infarction:+a+nationwide+study+&author=TK+Schramm&author=GH+Gislason&author=A+Vaag&author=JN+Rasmussen&author=F+Folke&author=ML+Hansen&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0099"> <div class="reference-title-banner"> <h4 class="title">Scott 2012</h4> </div> <div class="bibliography-section" id="CD012151-bib-0122"> <div class="citation-journal">Scott LJ. <span class="citation-title">Repaglinide: a review of its use in type 2 diabetes mellitus</span>. <span class="citation"> Drugs </span><span class="pubYear">2012</span>;<span class="volume">72</span>(2):249‐72. [PUBMED: 22268393] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22268393" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Repaglinide:+a+review+of+its+use+in+type+2+diabetes+mellitus&author=LJ+Scott&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0100"> <div class="reference-title-banner"> <h4 class="title">Selvin 2011</h4> </div> <div class="bibliography-section" id="CD012151-bib-0123"> <div class="citation-journal">Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. <span class="citation-title">Racial differences in glycemic markers: a cross‐sectional analysis of community‐based data</span>. <span class="citation"> Annals of Internal Medicine </span><span class="pubYear">2011</span>;<span class="volume">154</span>(5):303‐9. [PUBMED: 21357907] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21357907" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Racial+differences+in+glycemic+markers:+a+cross%E2%80%90sectional+analysis+of+community%E2%80%90based+data+&author=E+Selvin&author=MW+Steffes&author=CM+Ballantyne&author=RC+Hoogeveen&author=J+Coresh&author=FL+Brancati&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0101"> <div class="reference-title-banner"> <h4 class="title">Sterne 2011</h4> </div> <div class="bibliography-section" id="CD012151-bib-0124"> <div class="citation-journal">Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. <span class="citation-title">Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials</span>. <span class="citation"> BMJ </span><span class="pubYear">2011</span>;<span class="volume">343</span>:d4002. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21784880" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Recommendations+for+examining+and+interpreting+funnel+plot+asymmetry+in+meta%E2%80%90analyses+of+randomised+controlled+trials+&author=JA+Sterne&author=AJ+Sutton&author=JP+Ioannidis&author=N+Terrin&author=DR+Jones&author=J+Lau&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0102"> <div class="reference-title-banner"> <h4 class="title">UGDP 1976</h4> </div> <div class="bibliography-section" id="CD012151-bib-0125"> <div class="citation-journal">The University Group Diabetes Program. <span class="citation-title">A study of the effects of hypoglycemic agents on vascular complications in patients with adult‐onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide</span>. <span class="citation"> Diabetes </span><span class="pubYear">1976</span>;<span class="volume">25</span>:1129‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/992232" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0103"> <div class="reference-title-banner"> <h4 class="title">UKPDS 33 1998</h4> </div> <div class="bibliography-section" id="CD012151-bib-0126"> <div class="citation-journal">UK Prospective Diabetes Study (UKPDS) Group. <span class="citation-title">Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>(9131):837‐53. [PUBMED: 9742976] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9742976" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0104"> <div class="reference-title-banner"> <h4 class="title">UKPDS 34 1998</h4> </div> <div class="bibliography-section" id="CD012151-bib-0127"> <div class="citation-journal">UK Prospective Diabetes Study (UKPDS) Group. <span class="citation-title">Effect of intensive blood‐glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>(9131):854‐65. [PUBMED: 9742977] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9742977" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0105"> <div class="reference-title-banner"> <h4 class="title">Van de Laar 2006</h4> </div> <div class="bibliography-section" id="CD012151-bib-0128"> <div class="citation-journal">Laar FA, Lucassen PL, Akkermans RP, Lisdonk EH, Grauw WJ. <span class="citation-title">Alpha‐glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2006</span>;<span class="volume">4</span>:CD005061. [PUBMED: 17054235] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Alpha%E2%80%90glucosidase+inhibitors+for+people+with+impaired+glucose+tolerance+or+impaired+fasting+blood+glucose+&author=FA+Laar&author=PL+Lucassen&author=RP+Akkermans&author=EH+Lisdonk&author=WJ+Grauw&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0106"> <div class="reference-title-banner"> <h4 class="title">Viera 2011</h4> </div> <div class="bibliography-section" id="CD012151-bib-0129"> <div class="citation-journal">Viera AJ. <span class="citation-title">Predisease: when does it make sense?</span>. <span class="citation"> Epidemiologic Reviews </span><span class="pubYear">2011</span>;<span class="volume">33</span>:122‐34. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21624963" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Predisease:+when+does+it+make+sense?&author=AJ+Viera&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0107"> <div class="reference-title-banner"> <h4 class="title">Vist 2008</h4> </div> <div class="bibliography-section" id="CD012151-bib-0130"> <div class="citation-journal">Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD. <span class="citation-title">Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2008</span>, Issue 3. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.MR000009.pub4" target="_blank"><span>10.1002/14651858.MR000009.pub4</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Outcomes+of+patients+who+participate+in+randomized+controlled+trials+compared+to+similar+patients+receiving+similar+interventions+who+do+not+participate+&author=GE+Vist&author=D+Bryant&author=L+Somerville&author=T+Birminghem&author=AD+Oxman&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0108"> <div class="reference-title-banner"> <h4 class="title">Wetterslev 2008</h4> </div> <div class="bibliography-section" id="CD012151-bib-0131"> <div class="citation-journal">Wetterslev J, Thorlund K, Brok J, Gluud C. <span class="citation-title">Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2008</span>;<span class="volume">61</span>(1):64‐75. [PUBMED: 18083463] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18083463" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Trial+sequential+analysis+may+establish+when+firm+evidence+is+reached+in+cumulative+meta%E2%80%90analysis+&author=J+Wetterslev&author=K+Thorlund&author=J+Brok&author=C+Gluud&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0109"> <div class="reference-title-banner"> <h4 class="title">WHO 1998</h4> </div> <div class="bibliography-section" id="CD012151-bib-0132"> <div class="citation-journal">Alberti KM, Zimmet PZ. <span class="citation-title">Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">1998</span>;<span class="volume">15</span>(7):539‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9686693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Definition,+diagnosis+and+classification+of+diabetes+mellitus+and+its+complications.+Part+I:+diagnosis+and+classification+of+diabetes+mellitus.+Provisional+report+of+a+WHO+consultation+&author=KM+Alberti&author=PZ+Zimmet&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0110"> <div class="reference-title-banner"> <h4 class="title">WHO 1999</h4> </div> <div class="bibliography-section" id="CD012151-bib-0133"> <div class="citation-book">World Health Organization. <span class="citation">Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus</span>. WHO, <span class="pubYear">1999</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0111"> <div class="reference-title-banner"> <h4 class="title">WHO/IDF 2006</h4> </div> <div class="bibliography-section" id="CD012151-bib-0134"> <div class="citation-other">World Health Organization/ International Diabetes Federation. <span class="citation-title">Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation</span>. www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf (accessed 10 October 2015). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0112"> <div class="reference-title-banner"> <h4 class="title">Wong 2006a</h4> </div> <div class="bibliography-section" id="CD012151-bib-0135"> <div class="citation-journal">Wong SS, Wilczynski NL, Haynes RB. <span class="citation-title">Comparison of top‐performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE</span>. <span class="citation"> Journal of the Medical Library Association </span><span class="pubYear">2006</span>;<span class="volume">94</span>(4):451‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17082841" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+top%E2%80%90performing+search+strategies+for+detecting+clinically+sound+treatment+studies+and+systematic+reviews+in+MEDLINE+and+EMBASE+&author=SS+Wong&author=NL+Wilczynski&author=RB+Haynes&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0113"> <div class="reference-title-banner"> <h4 class="title">Wong 2006b</h4> </div> <div class="bibliography-section" id="CD012151-bib-0136"> <div class="citation-journal">Wong SSL, Wilczynski NL, Haynes RB. <span class="citation-title">Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE</span>. <span class="citation"> Journal of the Medical Library Association </span><span class="pubYear">2006</span>;<span class="volume">94</span>(1):41‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16404468" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Developing+optimal+search+strategies+for+detecting+clinically+sound+treatment+studies+in+EMBASE+&author=SSL+Wong&author=NL+Wilczynski&author=RB+Haynes&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0114"> <div class="reference-title-banner"> <h4 class="title">Wood 2008</h4> </div> <div class="bibliography-section" id="CD012151-bib-0137"> <div class="citation-journal">Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. <span class="citation-title">Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study</span>. <span class="citation"> BMJ </span><span class="pubYear">2008</span>;<span class="volume">336</span>(7644):601‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18316340" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Empirical+evidence+of+bias+in+treatment+effect+estimates+in+controlled+trials+with+different+interventions+and+outcomes:+meta%E2%80%90epidemiological+study+&author=L+Wood&author=M+Egger&author=LL+Gluud&author=KF+Schulz&author=P+J%C3%BCni&author=DG+Altman&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012151-bbs2-0115"> <div class="reference-title-banner"> <h4 class="title">Yudkin 2014</h4> </div> <div class="bibliography-section" id="CD012151-bib-0138"> <div class="citation-journal">Yudkin JS, Montori VM. <span class="citation-title">The epidemic of pre‐diabetes: the medicine and the politics</span>. <span class="citation"> BMJ </span><span class="pubYear">2014</span>;<span class="volume">349</span>:g4485. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25028385" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+epidemic+of+pre%E2%80%90diabetes:+the+medicine+and+the+politics&author=JS+Yudkin&author=VM+Montori&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD012151-bbs1-0004"> <h3 class="title">References to other published versions of this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD012151-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD012151-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD012151-bbs1-0003">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_otherVersions" id="CD012151-bbs2-0116"> <div class="reference-title-banner"> <h4 class="title">Hemmingsen 2016c</h4> </div> <div class="bibliography-section" id="CD012151-bib-0139"> <div class="citation-journal">Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. <span class="citation-title">Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2016</span>, Issue 4. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD012151" target="_blank"><span>10.1002/14651858.CD012151</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Insulin+secretagogues+for+prevention+or+delay+of+type+2+diabetes+mellitus+and+its+associated+complications+in+persons+at+increased+risk+for+the+development+of+type+2+diabetes+mellitus+&author=B+Hemmingsen&author=DP+Sonne&author=MI+Metzendorf&author=B+Richter&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD012151-sec2-0037"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD012151-sec2-0038" class="jump-to">excluded studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Eriksson 2006 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: first‐degree relatives of people with T2DM; age 35–70 years; BMI 25–35 kg/m<sup>2</sup>; fulfilling WHO criteria for IGT on two consecutive OGTTs </p> <p><b>Exclusion criteria</b>: other endocrine, renal, hepatic or inter‐current diseases </p> <p><b>Diagnostic criteria</b>: WHO criteria for IGT on two consecutive OGTTs (fasting plasma glucose &lt; 7.0 mmol/L and 2‐hour plasma glucose ≥ 7.8 mmol/L and &lt; 11.1 mmol/L) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Number of study centres</b>: 1 </p> <p><b>Run‐in period</b>: none, but all participants had to fulfill the diagnostic criteria for IGT prior to randomisation. OGTT was performed 12 months later (e.g. study baseline and confirmed the IGT diagnosis), after which the participants were randomised </p> <p><b>Administration‐free period before testing during trial:</b> not specified if any study drug was taken on the testing day at the end of the intervention. However, a 12 retesting was done 12 months after the end of the intervention </p> <p><b>Extension period</b>: participants were observed 1 year after the intervention was stopped </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early:</b> no </p> <p><b>Trial ID:</b> NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding:</b> commercial funding: grants from Orion Pharmaceuticals / non‐commercial funding: grant from the Sigrid Juselius Foundation, the Finnish Diabetes Research Society </p> <p><b>Publication status:</b> peer‐reviewed journal/full article </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Quote from publication: "Given these considerations, we designed a placebo‐controlled study with the aim of assessing the effect of an insulin secretagogue, i.e. glipizide, on glucose and insulin metabolism in glucose‐intolerant first‐degree relatives of patients with type 2 diabetes" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "... the subject was randomized to receive either glipizide 2.5 mg or placebo once daily" </p> <p><b>Comment:</b> method of randomisation not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "... the subject was randomized to receive either glipizide 2.5 mg or placebo once daily" </p> <p><b>Comment:</b> method of allocation not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "A similar number of subjects in both groups reported hypoglycaemic symptoms (e.g. hunger, fatigue, palpitations, tremor) during the study" </p> <p><b>Comment:</b> self‐reported outcome measurement. Blinding of participants was ensured by placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "After 6 months, i.e. at termination of drug treatment, both the OGTT and the IVGTT were repeated on different occasions 1 week apart. The participants continued without study drugs and an OGTT was performed at 18 months from baseline, i.e. 12 months after discontinuation of study medication" </p> <p><b>Comment:</b> investigator‐assessed. Blinding of investigators was ensured by placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "...placebo‐controlled study with the aim of assessing..."<br> <b>Comment:</b> investigator‐assessed. Blinding of participants and investigators was ensured by placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "All other side effects were mild" and "...placebo‐controlled study with the aim of assessing..." </p> <p><b>Comment:</b> self‐reported outcome measurement. Blinding of participants and investigators was ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "A similar number of subjects in both groups reported hypoglycaemic symptoms (e.g. hunger, fatigue, palpitations, tremor) during the study" </p> <p><b>Comment:</b> self‐reported outcome measurement. Blinding of participants was ensured by use of placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "After 6 months, i.e. at termination of drug treatment, both the OGTT and the IVGTT were repeated on different occasions 1 week apart. The participants continued without study drugs and an OGTT was performed at 18 months from baseline, i.e. 12 months after discontinuation of study medication" </p> <p><b>Comment:</b> investigator‐assessed. Blinding of investigators was ensured by placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> investigator‐assessed at baseline and after 6 and 18 months.Blinding of investigators was ensured by placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "All other side effects were mild" </p> <p><b>Comment:</b> self‐reported outcome measurement. Blinding of participants was ensured by placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "Three subjects dropped out early in the intervention – one because of hypoglycaemia, one because of an aortic aneurysm and one because of systemic lupus erythematosus and concomitant peroral corticosteroid treatment" and "One subject in the glipizide treatment group discontinued the study early due to hypoglycaemic symptoms" </p> <p><b>Comment:</b> two persons withdrew due to hypoglycaemia in the glipizide group. The two dropouts could have a substantial impact on the effect estimate for hypoglycaemia </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "Three subjects dropped out early in the intervention – one because of hypoglycaemia, one because of an aortic aneurysm and one because of systemic lupus erythematosus and concomitant peroral corticosteroid treatment" and "One subject in the glipizide treatment group discontinued the study early due to hypoglycaemic symptoms" </p> <p><b>Comment:</b> reported and reasons explained. Number of dropouts could influence this outcome </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "Three subjects dropped out early in the intervention – one because of hypoglycaemia, one because of an aortic aneurysm and one because of systemic lupus erythematosus and concomitant peroral corticosteroid treatment" and "One subject in the glipizide treatment group discontinued the study early due to hypoglycaemic symptoms" </p> <p><b>Comment:</b> reported and reasons explained. Number too low to have impact on clinical relevance </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "Three subjects dropped out early in the intervention – one because of hypoglycaemia, one because of an aortic aneurysm and one because of systemic lupus erythematosus and concomitant peroral corticosteroid treatment" and "One subject in the glipizide treatment group discontinued the study early due to hypoglycaemic symptoms" </p> <p><b>Comment:</b> reported and reasons explained. However, no data for non‐serious adverse events are available, so the impact of the missing data can not be evaluated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No trial protocol available. Non‐serious adverse events are reported incompletely, so these data can not be included in this review. Two participants dropped out due to hypoglycaemia, one of these allocated to the glipizide intervention group. Not described whether it was due to repetitive mild hypoglycaemia or severe hypoglycaemia </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> commercial funding </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NANSY 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: 40–70 years, IFG defined by two (10‐h overnight) consecutive fasting blood glucose values ≥ 5.6 mmol/L </p> <p><b>Exclusion criteria</b>: myocardial infarction or stroke during the last 12 months, heart failure NYHA III‐IV, endocrine disease, impaired renal function (serum creatinine ≥ 130 mmol/L), impaired hepatic function, mental condition interfering with ability to participate, treatment with oral glucocorticoids, current or planned pregnancy or breastfeeding, progressive serious disease </p> <p><b>Diagnostic criteria</b>: IFG defined by two (10‐h overnight) consecutive fasting blood glucose values ≥ 5.6 mmol/L with an arithmetic mean within 5.6 to 6.0 mmol/L </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Number of study centres</b>: 23 </p> <p><b>Run‐in period</b>: none </p> <p><b>Administration‐free period before testing during trial:</b> received study‐drug on the day of testing blood glucose for conversion to T2DM </p> <p><b>Extension period</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early:</b> no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding:</b> commercial funding (unrestricted starting grant from Hoechst‐Marion‐Roussel (now Sanofi‐Aventis)) and non‐commercial funding </p> <p><b>Publication status:</b> peer‐reviewed journal/full article (research letter) and abstract </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Quote from publication: "The Nepi ANtidiabetes StudY (NANSY) is a randomized, double‐blind and placebo‐controlled prospective trial assessing whether the addition of a once‐daily low dose of SU to lifestyle changes in subjects with IFG will help to delay the conversion to T2D" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Randomisation of participants was slower than expected. A NANSY‐eye subprotocol was published; however, final data are not available. Blood glucose values in this trial were reported as whole blood glucose. In the tables and result section all values are converted to plasma glucose values (<a href="references#CD012151-bbs2-0054">diabetes.co.uk 2016a</a>) </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "Patients were randomly assigned to glimepiride (Amaryl<sup>®</sup> from Hoechst‐Marion Roussel, now Sanofi‐Aventis) 1 mg or placebo once a day for 5 years" </p> <p><b>Comment:</b> method of randomisation not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "Patients were randomly assigned to glimepiride (Amaryl<sup>®</sup> from Hoechst‐Marion Roussel, now Sanofi‐Aventis) 1 mg or placebo once a day for 5 years" </p> <p><b>Comment:</b> method of allocation not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "...a randomized, double‐blind and placebo‐controlled prospective trial assessing..." </p> <p><b>Comment:</b> investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "...a randomized, double‐blind and placebo‐controlled prospective trial assessing..." </p> <p><b>Comment:</b> investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "...a randomized, double‐blind and placebo‐controlled prospective trial assessing..." </p> <p><b>Comment:</b> investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "...a randomized, double‐blind and placebo‐controlled prospective trial assessing..." </p> <p><b>Comment:</b> investigator‐assessed </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "Seventy‐one subjects interrupted participation prematurely; 7 interruptions were on account of death, 5 among subjects allocated to glimepiride and 2 among those allocated to placebo" </p> <p><b>Comment:</b> only reported, but it is assumed that mortality status was known on the participants who left the trial </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "Seventy‐one subjects interrupted participation prematurely..." </p> <p><b>Comment:</b> only reported. Not known to which intervention group the participants who stopped prematurely were randomised or the reasons. Assuming the diabetes status was unknown for the participants who dropped out </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> clear that fasting blood glucose was measured, however, no data were reported. HbA1c reported as no significant difference between the intervention groups (see <a href="appendices#CD012151-sec2-0023">Appendix 8</a>) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> commercial funding </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NAVIGATOR 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Factorial randomised controlled clinical trial, randomisation ratio 1:1, superiority design </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: written informed consent to participate; females must be surgically sterile or postmenopausal; 50 years or older; presence of cardiovascular risk factors (see notes) or cardiovascular disease(s) (see notes) at visit 1 (age 50 to 54 years ‐ 1 or more cardiovascular disease(s); age 55 years and older ‐ 1 or more cardiovascular risk factors or 1 or more cardiovascular disease(s)); fasting plasma glucose &gt; 5.3 mmol/L and &lt; 7.0 mmol/L at visit 1; 2 hour post‐challenge glucose (after a 75‐g OGTT) ≥ 7.8 mmol/L but &lt; 11.1 mmol/L at visit 1; ability and willingness to comply with all study requirements </p> <p><b>Exclusion criteria</b>: failure to provide written informed consent; evidence of hepatic disease defined as serum glutamic oxaloacetic transaminase or serum glutamic‐pyruvic transaminase &gt; 2 times the upper limit of normal at visit 1; renal failure with a serum creatinine &gt; 221 μmol/L at visit 1; clinically significant laboratory abnormalities that may interfere with the assessment of safety, efficacy, or both of the study drug, other than hyperglycaemia, hyperinsulinaemia and glycosuria; individuals requiring thyroid hormone replacement who have been on their current medication dosage for &lt; 3 months prior to month –1; history of malignancy including leukaemia or lymphoma (but not basal cell skin cancer) within the past 5 years; individuals on an angiotensin‐converting enzyme inhibitor for hypertension who are unable or unwilling to discontinue the medication under supervision of their physician at least 4 weeks prior to screening and during the full course of double‐blind treatment. A subject may be washed out from an angiotensin‐converting enzyme inhibitor only, if in the investigator’s opinion, it is in the best interest of the subject and/or the subject has been intolerant to the angiotensin‐converting enzyme inhibitor. For those individuals taken off an angiotensin‐converting enzyme inhibitor with the intent to enter the individual in the study, written informed consent will be obtained at the time of discontinuation of medication (at least 4 weeks prior to the screening visit); individuals on an angiotensin receptor blocker who are unable or unwilling to discontinue the medication under supervision of their physician at least 4 weeks prior to screening and during the full course of double‐blind treatment. A subject may be washed out from an angiotensin receptor blocker only, if in the investigator’s opinion, it is in the best interest of the subject. For those individuals taken off an angiotensin receptor blocker with the intent to enter the individual in the study, written informed consent will be obtained at the time of discontinuation of medication (at least 4 weeks prior to the screening visit). It is the physician’s responsibility to appropriately monitor the individual during this period; use of oral antidiabetics or insulin within the past 5 years; history of clinically significant autoimmune disorders such as systemic lupus erythematosus; history of active substance or alcohol abuse within the past year; known hypersensitivity or contraindication to nateglinide or valsartan; history of non‐compliance to medical regimens and/or individuals who are considered potentially unreliable; previous investigational drug treatment within the past month, unless local health authorities mandate a longer period; congestive heart failure NYHA class 3 or 4; presence of any concomitant condition which, in the opinion of the investigator or the sponsor, could interfere with the interpretation of efficacy and safety data gathered in this trial; chronic (&gt; 7 days) concomitant use of oral corticosteroids within 1 month prior to screening; myocardial infarction, diagnosis of stable or unstable angina, multivessel percutaneous transluminal coronary angioplasty or coronary artery bypass grafting, limb bypass surgery or percutaneous angioplasty, non traumatic limb or foot amputation, or stroke of atherosclerotic origin within 4 weeks prior to visit 1 and the time period between visit 1 and visit 2 </p> <p><b>Diagnostic criteria</b>: fasting plasma glucose ≥ 5.3 mmol/L and &lt; 7.0 mmol/L at visit 1 and 2‐hour post‐challenge glucose (after a 75‐g OGTT) ≥ 7.8 mmol/L but &lt; 11.1 mmol/L at visit 1 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Number of study centres</b>: 806 </p> <p><b>Run‐in period</b>: 4 weeks (at visit 1, eligible people entered a treatment‐free run‐in period for up to 4 weeks) </p> <p><b>Administration‐free period before testing during trial:</b> participants were asked not to take study drug on the testing days until after the glucose tests had been performed </p> <p><b>Extension period</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: yes </p> <p>Two composite primary cardiovascular outcomes are reported:</p> <p>‐ extended cardiovascular endpoint (the time to first occurrence of a cardiovascular morbidity/mortality event (including cardiovascular death, non‐fatal myocardial infarction, non‐fatal stroke, revascularisation procedure, hospitalisation for congestive heart failure, hospitalisation for unstable angina) </p> <p>‐ core cardiovascular endpoint (the time to first occurrence of a cardiovascular morbidity/mortality event (cardiovascular death, myocardial infarction, stroke or hospitalisation for congestive heart failure) </p> <p>The 'core' cardiovascular endpoint was initially a secondary outcome, but was added during the trial </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early:</b> no </p> <p><b>Trial ID:</b> NCT00097786 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding:</b> commercial funding (Novartis Pharma) </p> <p><b>Publication status:</b> peer‐reviewed journal </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Quote from publication: "The aim of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial<sup>11</sup> was to determine whether the risk of diabetes and cardiovascular events could be reduced in this population" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Cardiovascular risk factors: family history of premature coronary heart disease (definite myocardial infarction or sudden death before 55 years of age in father or other male first‐degree relative, or before 65 years of age in mother or other female first‐degree relative); current cigarette smoking (defined as smoking at least 10 cigarettes/day on a regular basis for at least 5 years prior to inclusion in the study; if the individual has quit smoking, s/he will be considered a smoker if s/he stopped less than 12 months before inclusion); hypertension (&gt; 140 mmHg systolic or 90 mmHg diastolic or on antihypertensive medication); low HDL cholesterol (&lt; 1.0 mmol/L); high LDL (≥ 4.1 mmol/L) or high non‐HDL (&gt; 4.9 mmol/L) if triglycerides are &gt; 2.3 mmol/L or on lipid‐lowering therapy; left ventricular hypertrophy with strain pattern defined as per electrocardiogram (Sokolow and Lyon criteria or Cornell criteria); known microalbuminuria (&gt; 30 mg/g creatinine) </p> <p>Cardiovascular disease(s): previous myocardial infarction (&gt; 1 month ago); stable angina or unstable angina (&gt; 1 month ago) each with documented multivessel coronary disease; &gt; 50% stenosis in at least two major coronary arteries, or positive stress test; multivessel percutaneous transluminal coronary angioplasty &gt; 1 month ago; multivessel coronary artery bypass grafting &gt; 4 years ago or with angina; previous limb bypass surgery or percutaneous angioplasty; previous non‐traumatic limb or foot amputation; history of intermittent claudication with ankle:arm blood pressure ratio of &lt; 0.80 in at least one side; significant peripheral stenosis (&gt; 50%) documented by angiography; stroke of atherosclerotic origin &gt; 1 month ago </p> <p>The trial had a <b>factorial design</b> randomising participants to 1) nateglinide + valsartan; 2) nateglinide + valsartan‐placebo; 3) nateglinide‐placebo + valsartan; 4) nateglinide‐placebo + valsartan‐placebo </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "We used a computerized, interactive voice‐response telephone randomization system involving concealed study‐group assignments to randomly assign patients to valsartan or matching placebo (and nateglinide or matching placebo) in a 2‐by‐2 factorial design. Randomization was stratified according to center, with a block size of eight within each center" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "We used a computerized, interactive voice‐response telephone randomization system involving concealed study‐group assignments to randomly assign patients to valsartan or matching placebo (and nateglinide or matching placebo) in a 2‐by‐2 factorial design. Randomization was stratified according to center, with a block size of eight within each center" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "The double‐blinding of the randomized study medication will be maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively" </p> <p><b>Comment:</b> adjudicated outcome measurement. Blinding of participants and investigators ensured </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> amputation, blindness/severe vision loss, end‐stage renal disease </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "The double‐blinding of the randomized study medication will be maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively" </p> <p><b>Comment:</b> adjudicated/investigator‐assessed. Blinding of participants and investigators ensured </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "A qualified person must review diary entries with the patient at each visit to determine if the signs and symptoms are consistent with hypoglycemia" </p> <p><b>Comment:</b> investigator‐assessed/self‐reported outcome measurement. Blinding of participants and investigators ensured </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "The double‐blinding of the randomized study medication will be maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively" </p> <p><b>Comment:</b> adjudicated/investigator‐assessed outcome measurement. Blinding of participants and investigators ensured </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "The double‐blinding of the randomized study medication will be maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively" and "The fasting plasma glucose level or the plasma<br> glucose level 2 hours after a glucose challenge was measured at the closeout visit or during the final 6 months of..."<br> <b>Comment:</b> adjudicated/investigator‐assessed outcome measurement. Blinding of participants and investigators ensured </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> non‐fatal myocardial infarction/stroke, congestive heart failure </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "The double‐blinding of the randomized study medication will be maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively"<br> <b>Comment:</b> adjudicated outcome measurement. Blinding of participants and investigators ensured </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "The double‐blinding of the randomized study medication will be maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively"<br> <b>Comment:</b> self‐reported/investigator‐assessed outcome measurement. Blinding of participants and investigators ensured </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "The double‐blinding of the randomized study medication will be maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively"<br> <b>Comment:</b> adjudicated/investigator‐assessed outcome measurement. Blinding of participants and investigators ensured </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> time to progression to T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "The double‐blinding of the randomized study medication will be maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively"<br> <b>Comment:</b> adjudicated/investigator‐assessed outcome measurement. Blinding of participants and investigators ensured </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "Occurrence of a suspected morbidity/mortality endpoint will be reported by the investigator and adjudicated by the Cardiovascular Endpoint Committee. Only Adjudication Committee‐confirmed events can be considered for this primary endpoint" </p> <p><b>Comment:</b> adjudicated/investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> amputation, blindness/severe vision loss, end‐stage renal disease </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> adjudicated/investigator‐assessed. Only blindness reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "A qualified person must review diary entries with the patient at each visit to determine if the signs and symptoms are consistent with hypoglycemia" </p> <p><b>Comment:</b> adjudicated/investigator‐assessed/self‐reported outcome measurement. Blinding ensured for participant, investigators and outcome assessors </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "Adjudication by the Diabetes Endpoint Adjudication Committee: progression to diabetes may be confirmed by the Committee in cases suggestive of diabetes but where above laboratory test‐based definition does not hold (e.g. due to missing central laboratory measurements or repeat tests outside the 12‐week time limit). E.g., the Committee will adjudicate cases where diabetes has been diagnosed by a primary care physician (possibly based on local laboratory assessments) and/or where anti‐diabetic medication has been initiated; adjudication also includes deciding on the time to progression to diabetes" and "The Diabetes Endpoint Adjudication Committee will be responsible for an independent and blinded assessment of all suspected cases of diabetes" </p> <p><b>Comment:</b> adjudicated, investigator‐assessed, or both </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "The progression to diabetes endpoint is defined through (a) an algorithm based on central laboratory measurements of FPG and/or 2hr OGTT, or (b) adjudication by the Diabetes Endpoint Adjudication Committee as follows..." and "The fasting plasma glucose level or the plasma glucose level 2 hours after a glucose challenge was measured at the closeout visit or during the final 6 months of..." </p> <p><b>Comment:</b> adjudicated/investigator‐assessed </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> non‐fatal myocardial infarction/stroke, congestive heart failure </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "Occurrence of a suspected morbidity/mortality endpoint will be reported by the investigator and adjudicated by the Cardiovascular Endpoint Committee. Only Adjudication Committee‐confirmed events can be considered for this primary endpoint" and "...to provide an independent and blinded assessment of the cardiovascular efficacy endpoints as defined..." </p> <p><b>Comment:</b> adjudicated outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "Information about all adverse events, whether volunteered by the subject, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected and recorded in the patient’s source documents and CRF and followed as appropriate"<br> <b>Comment:</b> self‐reported outcome measurement/investigator‐assessed </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> adjudicated/investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> time to progression of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "The progression to diabetes endpoint is defined through (a) an algorithm based on central laboratory measurements of FPG and/or 2hr OGTT, or (b) adjudication by the Diabetes Endpoint Adjudication Committee" </p> <p><b>Comment:</b> adjudicated/investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "Patients who are considered lost to follow‐up at one point in time will remain in the study until trial end or patient’s death, if known. At every scheduled visit until trial end or patient’s death, if known, every possible effort should be made to contact the patient (or patient’s relatives) to obtain visit information. At least vital status information, as a matter of public record in most countries, must be followed at every scheduled visit to the end of the study" and "After randomization, 212 participants at 10 sites were excluded when the sites were closed owing to deficiencies in the adherence to Good Clinical Practice guidelines, leaving 9306 participants whose data were included in the final analyses (Fig. 1)" and "A total of 609 participants in the nateglinide group (13.1%) and 602 in the placebo group (12.9%) were lost to follow‐up or withdrew from the study; however, because many of these participants were lost to follow‐up or withdrew consent late in the study, information on vital status was available for 95.7% of the possible follow‐up time in both groups" </p> <p><b>Comment:</b> missing outcomes balanced between intervention groups. However, reasons for missing data were not reported for the 163 persons in the nateglinide group and 143 persons in the placebo group </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> amputation, blindness/severe vision loss, end‐stage renal disease </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "After randomization, 212 participants at 10 sites were excluded when the sites were closed owing to deficiencies in the adherence to Good Clinical Practice guidelines, leaving 9306 participants whose data were included in the final analyses (Fig. 1)" and "A total of 609 participants in the nateglinide group (13.1%) and 602 in the placebo group (12.9%) were lost to follow‐up or withdrew from the study; however, because many of these participants were lost to follow‐up or withdrew consent late in the study, information on vital status was available for 95.7% of the possible follow‐up time in both groups" </p> <p><b>Comment:</b> missing outcomes balanced between intervention groups with similar reasons for missingness. However, unclear why 163 in the nateglinide group and 143 in the placebo group withdrew participation. Also, the overall attrition rate was high </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "After randomization, 212 participants at 10 sites were excluded when the sites were closed owing to deficiencies in the adherence to Good Clinical Practice guidelines, leaving 9306 participants whose data were included in the final analyses (Fig. 1)" and "A total of 609 participants in the nateglinide group (13.1%) and 602 in the placebo group (12.9%) were lost to follow‐up or withdrew from the study; however, because many of these participants were lost to follow‐up or withdrew consent late in the study, information on vital status was available for 95.7% of the possible follow‐up time in both groups" </p> <p><b>Comment:</b> missing outcomes balanced between intervention groups with similar reasons for missingness. However, unclear why 163 in the nateglinide group and 143 in the placebo group withdrew participation. Also, the overall attrition rate was high </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "After randomization, 212 participants at 10 sites were excluded when the sites were closed owing to deficiencies in the adherence to Good Clinical Practice guidelines, leaving 9306 participants whose data were included in the final analyses (Fig. 1)" and "A total of 609 participants in the nateglinide group (13.1%) and 602 in the placebo group (12.9%) were lost to follow‐up or withdrew from the study; however, because many of these participants were lost to follow‐up or withdrew consent late in the study, information on vital status was available for 95.7% of the possible follow‐up time in both groups" </p> <p><b>Comment:</b> missing outcomes balanced between intervention groups with similar reasons for missingness. However, unclear why 163 in the nateglinide group and 143 in the placebo group withdrew participation. Also, the overall attrition rate was high </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "After randomization, 212 participants at 10 sites were excluded when the sites were closed owing to deficiencies in the adherence to Good Clinical Practice guidelines, leaving 9306 participants whose data were included in the final analyses (Fig. 1)" and "A total of 609 participants in the nateglinide group (13.1%) and 602 in the placebo group (12.9%) were lost to follow‐up or withdrew from the study; however, because many of these participants were lost to follow‐up or withdrew consent late in the study, information on vital status was available for 95.7% of the possible follow‐up time in both groups" </p> <p><b>Comment:</b> missing outcomes balanced between intervention groups with similar reasons for missingness. However, unclear why 163 in the nateglinide group and 143 in the placebo group withdrew participation. Also, the overall attrition rate was high </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> non‐fatal myocardial infarction/stroke, congestive heart failure </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "After randomization, 212 participants at 10 sites were excluded when the sites were closed owing to deficiencies in the adherence to Good Clinical Practice guidelines, leaving 9306 participants whose data were included in the final analyses (Fig. 1)" and "A total of 609 participants in the nateglinide group (13.1%) and 602 in the placebo group (12.9%) were lost to follow‐up or withdrew from the study; however, because many of these participants were lost to follow‐up or withdrew consent late in the study, information on vital status was available for 95.7% of the possible follow‐up time in both groups" </p> <p><b>Comment:</b> missing outcomes balanced between intervention groups with similar reasons for missingness. However, unclear why 163 in the nateglinide group and 143 in the placebo group withdrew participation. Also, the overall attrition rate was high </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "After randomization, 212 participants at 10 sites were excluded when the sites were closed owing to deficiencies in the adherence to Good Clinical Practice guidelines, leaving 9306 participants whose data were included in the final analyses (Fig. 1)" and "A total of 609 participants in the nateglinide group (13.1%) and 602 in the placebo group (12.9%) were lost to follow‐up or withdrew from the study; however, because many of these participants were lost to follow‐up or withdrew consent late in the study, information on vital status was available for 95.7% of the possible follow‐up time in both groups" </p> <p><b>Comment:</b> missing outcomes balanced between intervention groups with similar reasons for missingness. However, unclear why 163 in the nateglinide group and 143 in the placebo group withdrew participation. Also, the overall attrition rate was high </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "After randomization, 212 participants at 10 sites were excluded when the sites were closed owing to deficiencies in the adherence to Good Clinical Practice guidelines, leaving 9306 participants whose data were included in the final analyses (Fig. 1)" and "A total of 609 participants in the nateglinide group (13.1%) and 602 in the placebo group (12.9%) were lost to follow‐up or withdrew from the study; however, because many of these participants were lost to follow‐up or withdrew consent late in the study, information on vital status was available for 95.7% of the possible follow‐up time in both groups" </p> <p><b>Comment:</b> missing outcomes balanced between intervention groups with similar reasons for missingness. However, unclear why 163 in the nateglinide group and 143 in the placebo group withdrew participation. Also, the overall attrition rate was high </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> time to progression to T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "After randomization, 212 participants at 10 sites were excluded when the sites were closed owing to deficiencies in the adherence to Good Clinical Practice guidelines, leaving 9306 participants whose data were included in the final analyses (Fig. 1)" and "A total of 609 participants in the nateglinide group (13.1%) and 602 in the placebo group (12.9%) were lost to follow‐up or withdrew from the study; however, because many of these participants were lost to follow‐up or withdrew consent late in the study, information on vital status was available for 95.7% of the possible follow‐up time in both groups" </p> <p><b>Comment:</b> missing outcomes balanced between intervention groups with similar reasons for missingness. However, unclear why 163 in the nateglinide group and 143 in the placebo group withdrew participation. Also, the overall attrition rate was high </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> no reporting of HbA1c, end‐stage renal disease and health economics, even though it was stated these outcomes would be measured (see <a href="appendices#CD012151-sec2-0023">Appendix 8</a>) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> commercial funding </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Osei 2004 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: first‐degree relatives (offspring and siblings) of African American individuals with T2DM; IGT during OGTT </p> <p><b>Exclusion criteria</b>: diabetes, liver, heart, lung and kidney disease, participants taking part in endurance exercise or competitive sports </p> <p><b>Diagnostic criteria</b>: IGT was defined as fasting serum glucose &lt; 7.8 mmol/L and 2‐hour serum glucose after a 75‐g oral glucose challenge &gt; 7.8 but &lt; 11.1 mmol/L (WHO 1985) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Number of study centres</b>: 1 </p> <p><b>Run‐in period</b>: none, but the participants were instructed to follow specific meals at least 3 days before the test </p> <p><b>Administration free period before testing during trial:</b> participants were asked not to take the study drug on the mornings on which glycaemic measurements were performed. </p> <p><b>Extension period</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early:</b> no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding:</b> commercial funding (Pfizer Pharmaceutical Inc. supplied glipizide GITS) and non‐commercial funding </p> <p><b>Publication status:</b> peer‐reviewed journal </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Quote from publication: "Therefore, we tested the hypothesis that SU could reverse the early beta‐cell dysfunction and ultimately improve glucose homeostasis in high‐risk African‐American patients with IGT" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "After satisfying study entry requirements and baseline studies, the subjects were randomized in a double blind, placebo‐controlled manner to receive either GITS (5 mg/d or identical placebo for 24 months" </p> <p><b>Comment:</b> method of randomisation not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "After satisfying study entry requirements and baseline studies, the subjects were randomized in a double blind, placebo‐controlled manner to receive either GITS (5 mg/d or identical placebo for 24 months" </p> <p><b>Comment:</b> method of allocation not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "Thus, symptoms suggestive of hypoglycaemia (e.g., nervousness, excessive hunger, tremors, confusion, etc) were recorded in a logbook..." </p> <p><b>Comment:</b> self‐reported outcome measurement. Blinding of participants was ensured by placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> investigator‐assessed. Blinding of participants was ensured by placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "Thus, symptoms suggestive of hypoglycaemia (e.g., nervousness, excessive hunger, tremors, confusion, etc) were recorded in a logbook..." </p> <p><b>Comment:</b> self‐reported outcome measurement. Blinding of participants was ensured by use of placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> investigator‐assessed.Blinding of participants was ensured by placebo tablets </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> described that no participants had symptoms suggestive of hypoglycaemia. Not reported if any data were missing </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> no trial protocol available </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> commercial funding </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Page 1993 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel randomised controlled clinical trial, randomisation ratio 1:1:3 (see notes), superiority design </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: family history of T2DM, previously gestational diabetes or a previously raised plasma glucose (5.6 to 6.6 mmol/L) with hyperglycaemia on two separate glucose tolerance tests </p> <p><b>Exclusion criteria</b>: fasting plasma glucose &gt; 7 mmol/L, diastolic blood pressure &gt; 105 mmHg, treatment with thiazide diuretics, beta‐blockers or calcium antagonists, angina or previously myocardial infarction, lung disease and inability to participate in VO<sub>2</sub> measurements, pregnancy, vigorous exercise three or more times per week for a period of 30 minutes or more or participating in regular manual work, BMI &lt; 20 kg/m<sup>2</sup>, coexisting chronic disease requiring therapy which would prevent participation </p> <p><b>Diagnostic criteria</b>: fasting plasma glucose &gt; 5.6 mmol/L and (or age‐corrected) achieved plasma glucose during continuous infusion of glucose ( 60 minutes) with model assessment above 9.3 mmol/L. According to the authors this value has been show to be equivalent to the WHO's criteria for impaired glucose tolerance </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Number of study centres</b>: NR </p> <p><b>Run‐in period</b>: none </p> <p><b>Administration‐free period before testing during trial:</b> participants were asked not to take the study drug on the morning of the glycaemic measurement at 6 weeks and at 6 months. Participants were retested 4 weeks after the end of the intervention period </p> <p><b>Extension period</b>: yes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early:</b> no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding:</b> commercial funding (Servier) and non‐commercial funding </p> <p><b>Publication status:</b> peer‐reviewed journal </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Quote from publication: "The objectives of this study were: to determine whether when given access to exercise classes, dietary advice and verbal support it is possible to alter the lifestyle of subjects with IGT; to determine whether regular exercise and aiming for an ideal body weight by a high fibre, low fat, high carbohydrate diet will improve plasma glucose levels and cardiovascular risk factors in subjects with impaired glucose tolerance; and to determine whether sulphonylurea therapy with gliclazide 40 mg twice daily is more or less effective than healthy living in improving glucose tolerance and cardiovascular risk factors" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>For the initial 6 weeks, the healthy living group was divided into three subgroups; diet only; exercise only; and diet and exercise. After 6 weeks all three healthy living intervention groups participated in both diet and exercise for the remaining 6 months of the trial </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "Subjects were randomized into three main groups..." and "Despite randomization, the groups showed disparities in baseline characteristics, and this may lead to error in the interpretation of the results" </p> <p><b>Comment:</b> method of randomisation not described. However, important differences exist in some baseline characteristics, but the uneven distribution does not appear to be in favour of any of the intervention groups </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quotes from publication:</b> "Subjects were randomized into three main groups..." and "Despite randomization, the groups showed disparities in baseline characteristics, and this may lead to error in the interpretation of the results" </p> <p><b>Comment:</b> method of allocation not described. However, important differences exist in some baseline characteristics, but the uneven distribution does not appear to be in favour of any of the intervention groups </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "No hypoglycaemic episodes were reported in any group"<br> <b>Comment:</b> self‐reported outcome measurement. For the comparison of gliclazide and placebo the participants in both groups and investigators were blinded. However, the participants and investigators were aware of the allocation to the diet and exercise intervention </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> investigator‐assessed outcome measurement. For the comparison of gliclazide and placebo the participants in both groups and investigators were blinded. However, the participants and investigators were aware of the allocation to the diet and exercise intervention. The outcome is unlikely to be influenced by the lack of blinding </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> self‐reported outcome measurement. For the comparison of gliclazide and placebo the participants in both groups and investigators were blinded. However, the participants and investigators were aware of the allocation to the diet and exercise intervention </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> investigator‐assessed outcome measurement. For the comparison of gliclazide and placebo the participants in both groups and investigators were blinded. However, the participants and investigators were aware of the allocation to the diet and exercise intervention. The outcome is unlikely to be influenced by the lack of blinding </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "One subject in the placebo withdrew before 6‐week assessment due to prolonged holiday and non‐compliance, and three subjects withdrew from the healthy living groups before this time: one became pregnant, one found the time commitment too great and one was apprehensive about blood test. After 6 weeks no subject withdrew from the 'healthy living' group, due to the commitment required to participate in the study" </p> <p><b>Comment:</b> reasons reported and explained. It is not possible to assess whether the missing data are likely to introduce bias </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "One subject in the placebo withdrew before 6‐week assessment due to prolonged holiday and non‐compliance, and three subjects withdrew from the healthy living groups before this time: one became pregnant, one found the time commitment too great and one was apprehensive about blood test. After 6 weeks no subject withdrew from the 'healthy living' group, due to the commitment required to participate in the study" </p> <p><b>Comment:</b> reasons reported and explained. It is not possible to assess whether the missing data are likely to introduce bias </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> according to the publication HbA1c was measured and analysed, but the result is reported only as a non‐significant change (see <a href="appendices#CD012151-sec2-0021">Appendix 6</a>) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> commercial funding </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Papoz 1978 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Parallel randomised controlled clinical trial, randomisation ratio 1:1, superiority design </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: male, 25 to 55 years, 'borderline' diabetes (see criteria in the section 'diagnostic criteria') </p> <p><b>Exclusion criteria</b>: NR </p> <p><b>Diagnostic criteria</b>: fasting blood glucose ≥ 5.6 mmol/L and &lt; 7.2 mmol/L or 2‐hour blood glucose after a 75‐g oral glucose challenge ≥ 6.7 mmol/L and &lt; 8.3 mmol/L; when these criteria for intermediate hyperglycaemia were fulfilled, a second test was performed: blood glucose concentrations were determined fasting at 15, 30, 60, 120, 80, 240 and 300 minutes after an oral glucose load. Eligible individuals had 2‐hour blood glucose concentrations ≥ 6.7 mmol/L but &lt; 8.3 mmol/L or fasting blood glucose concentrations ≥ 5.6 mmol/L and &lt; 7.2 mmol/L; blood glucose after 30 minutes ≥ 8.9 mmol/L and &lt; 12.2 mmol/L; blood glucose after 60 minutes ≥ 8.9 mmol/L and &lt; 12.2 mmol/L (the European Diabetes Epidemiology Study Group 1970 criteria) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Number of study centres</b>: 1 </p> <p><b>Run‐in period</b>: none </p> <p><b>Administration‐free period before testing during trial:</b> participants received study‐drug on the day of testing blood glucose at 2 months and 14 months. However, the last glycaemic measurements were performed 15 days after the study drug was stopped </p> <p><b>Extension period</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early:</b> no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding:</b> non‐commercial funding </p> <p><b>Publication status:</b> peer‐reviewed journal </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Quote from publication: "A double blind controlled clinical trial was undertaken to test the effectiveness of oral hypoglycaemic drugs in improving blood glucose and plasma insulin levels of borderline diabetic patients" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Blood glucose values in this trial were reported as whole blood glucose. In the tables and result section all values are converted to plasma glucose values (<a href="references#CD012151-bbs2-0054">diabetes.co.uk 2016a</a>) </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "They were randomized into 4 groups according..." </p> <p><b>Comment:</b> method of randomisation not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "They were randomized into 4 groups according..." </p> <p><b>Comment:</b> method of allocation not described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "A double blind controlled clinical trial was undertaken..." </p> <p><b>Comment:</b> investigator‐assessed, double‐blinding </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "A double blind controlled clinical trial was undertaken..." </p> <p><b>Comment:</b> investigator‐assessed, double‐blinding </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from publication:</b> "Thirty four patients (24 during the first year, 10 during the second year of the study) were lost to follow‐up; they came equally from the four different treatment groups and exhibited similar baseline characteristics to the follow‐up patients. Their removal from the trial did not introduce any bias into the study" </p> <p><b>Comment:</b> the number of participants lost to follow‐up are reported, but no reasons explained </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> likely that adverse events have been assessed, as the investigators describe no pathological symptoms occurred during the trial (see <a href="appendices#CD012151-sec2-0021">Appendix 6</a>) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment:</b> the trial appeared to be free of other sources of bias </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Note: where the judgement is 'unclear' and the description is blank, the trial did not report that particular outcome. </p> <p>BMI: body mass index; FPG: fasting plasma glucose; GITS: glipizide gastrointestinal therapeutic system; HbA1c: glycosylated haemoglobin A1c; HDL: high density lipoprotein; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; IVGTT: intravenous glucose tolerance test; LDL: low density lipoprotein; NANSY: The Nepi ANtidiabetes StudY; NAVIGATOR: Nateglinide+Valsartan to Prevent or Delay Type 2 Diabetes Mellitus and Cardiovascular Complications; NR: not reported; NYHA: New York Heart Association; OGTT: oral glucose tolerance test; SU: sulphonylurea; T2D(M): type 2 diabetes mellitus; VO<sub>2</sub>: maximum rate of oxygen consumption; WHO: World Health Organization </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD012151-sec2-0038"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD012151-sec2-0037" class="jump-to">included studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0007">Bavirti 2003</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0008">Bitzen 1988</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0009">Cederholm 1985</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants not randomised to treatment with glipizide</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0010">Cederholm 1986</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0011">DIANA 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not possible to get separate data on the participants with impaired glucose tolerance (investigator did not reply) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0012">Gudipaty 2014</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All participants had a history of type 2 diabetes mellitus</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0013">Hirose 2002</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0014">Igata 2014</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not possible to get separate data on the participants with impaired glucose tolerance (investigators did not reply) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0015">Inoue 1997</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0016">Johanson 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Did not have impaired fasting glucose, impaired glucose tolerance or moderately elevated HbA1c as an inclusion criterion </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0017">Katahira 2005</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0018">Lindblad 2001</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration of the intervention less than 12 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0019">Major‐Pedersen 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not possible to get separate data on the participants with impaired glucose tolerance (investigators contacted, and replied, but no data were provided) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0020">NCT00744965</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Includes pregnant women with gestational diabetes</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0021">NCT01563120</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Includes pregnant women with gestational diabetes</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0022">Pontiroli 1991</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0023">Ratzmann 1981</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0024">Ratzmann 1983</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0025">Saloranta 2002</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration of the intervention less than 12 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0026">Schmoelzer 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration of the intervention less than 12 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012151-bbs2-0027">The Fasting Hyperglycaemia Study 1997a</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not possible to get separate data on the participants with impaired glucose tolerance (Rury Holman was asked and replied) </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD012151-sec1-0011"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD012151-tbl-0003"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Sulphonylureas as monotherapy vs placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of type 2 diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>307</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.75 [0.54, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-01.png?filename=nCD012151-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%201%20Incidence%20of%20type%202%20diabetes.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"><img data-id="CD012151-fig-00101" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-01.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 1 Incidence of type 2 diabetes."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 1 Incidence of type 2 diabetes. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Mild hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00102"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-02.png?filename=nCD012151-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%202%20Mild%20hypoglycaemia.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.2</div> </div> <hr class="top"><img data-id="CD012151-fig-00102" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-02.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 2 Mild hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 2 Mild hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00103"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-03.png?filename=nCD012151-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%203%20Severe%20hypoglycaemia.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.3</div> </div> <hr class="top"><img data-id="CD012151-fig-00103" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-03.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 3 Severe hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 3 Severe hypoglycaemia.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Fasting blood glucose control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 [‐0.59, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00104"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-04.png?filename=nCD012151-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%204%20Fasting%20blood%20glucose%20control.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.4</div> </div> <hr class="top"><img data-id="CD012151-fig-00104" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-04.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 4 Fasting blood glucose control."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 4 Fasting blood glucose control. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Fasting blood glucose control: type of SU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 [‐0.59, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00105"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-05.png?filename=nCD012151-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%205%20Fasting%20blood%20glucose%20control%3A%20type%20of%20SU.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.5</div> </div> <hr class="top"><img data-id="CD012151-fig-00105" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-05.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 5 Fasting blood glucose control: type of SU."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 5 Fasting blood glucose control: type of SU. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 Second‐generation SU</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>87</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.27 [‐0.57, 0.02]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 Third‐generation SU</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.70 [‐1.72, 0.32]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Fasting blood glucose control: duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 [‐0.59, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00106"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-06.png?filename=nCD012151-CMP-001-06.ppt&amp;title=1.6&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%206%20Fasting%20blood%20glucose%20control%3A%20duration%20of%20intervention.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.6</div> </div> <hr class="top"><img data-id="CD012151-fig-00106" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-06.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 6 Fasting blood glucose control: duration of intervention."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 6 Fasting blood glucose control: duration of intervention. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 duration less than 2 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>46</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.28 [‐0.95, 0.39]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 duration 2 years or more</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>59</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.35 [‐0.69, 0.00]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Fasting blood glucose control: diagnostic criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 [‐0.59, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00107"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-07.png?filename=nCD012151-CMP-001-07.ppt&amp;title=1.7&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%207%20Fasting%20blood%20glucose%20control%3A%20diagnostic%20criteria.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.7</div> </div> <hr class="top"><img data-id="CD012151-fig-00107" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-07.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 7 Fasting blood glucose control: diagnostic criteria."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 7 Fasting blood glucose control: diagnostic criteria. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 WHO diagnostic</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>51</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.22 [‐0.86, 0.42]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 Other criteria</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>54</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.36 [‐0.70, ‐0.02]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting blood glucose control: age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.48 [‐0.79, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00108"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-08.png?filename=nCD012151-CMP-001-08.ppt&amp;title=1.8&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%208%20Fasting%20blood%20glucose%20control%3A%20age.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.8</div> </div> <hr class="top"><img data-id="CD012151-fig-00108" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-08.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 8 Fasting blood glucose control: age."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 8 Fasting blood glucose control: age. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.1 age less than 50 yrs</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.62 [‐0.95, ‐0.30]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.2 age above 50 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [‐0.60, 0.60]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Extension period: fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>45</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.08 [‐1.04, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00109"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-09.png?filename=nCD012151-CMP-001-09.ppt&amp;title=1.9&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%209%20Extension%20period%3A%20fasting%20blood%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.9</div> </div> <hr class="top"><img data-id="CD012151-fig-00109" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-09.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 9 Extension period: fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 9 Extension period: fasting blood glucose. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 2‐hour glucose [mmol/L] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>92</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.42 [‐1.28, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00110"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-10.png?filename=nCD012151-CMP-001-10.ppt&amp;title=1.10&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%2010%202%E2%80%90hour%20glucose%20%5Bmmol%2FL%5D.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.10</div> </div> <hr class="top"><img data-id="CD012151-fig-00110" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-10.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 10 2‐hour glucose [mmol/L]."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 10 2‐hour glucose [mmol/L].</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 2‐hour glucose [mmol/L]: type of SU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>92</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.42 [‐1.28, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00111"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-11.png?filename=nCD012151-CMP-001-11.ppt&amp;title=1.11&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%2011%202%E2%80%90hour%20glucose%20%5Bmmol%2FL%5D%3A%20type%20of%20SU.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.11</div> </div> <hr class="top"><img data-id="CD012151-fig-00111" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-11.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 11 2‐hour glucose [mmol/L]: type of SU."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 11 2‐hour glucose [mmol/L]: type of SU. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.1 Second‐generation SU</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>74</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.16 [‐0.90, 0.57]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.2 Third‐generation SU</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.0 [‐4.20, 0.20]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 2‐hour glucose [mmol/L]: duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>92</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.42 [‐1.28, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00112"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-12.png?filename=nCD012151-CMP-001-12.ppt&amp;title=1.12&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%2012%202%E2%80%90hour%20glucose%20%5Bmmol%2FL%5D%3A%20duration%20of%20intervention.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.12</div> </div> <hr class="top"><img data-id="CD012151-fig-00112" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-12.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 12 2‐hour glucose [mmol/L]: duration of intervention."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 12 2‐hour glucose [mmol/L]: duration of intervention. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.1 Duration 2 years or more</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>59</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.75 [‐2.64, 1.15]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.2 Duration less than 2 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.40 [‐1.56, 0.76]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 2‐hour glucose [mmol/L]: diagnostic criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>92</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.42 [‐1.28, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012151-fig-00113"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-13.png?filename=nCD012151-CMP-001-13.ppt&amp;title=1.13&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%2013%202%E2%80%90hour%20glucose%20%5Bmmol%2FL%5D%3A%20diagnostic%20criteria.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.13</div> </div> <hr class="top"><img data-id="CD012151-fig-00113" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-13.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 13 2‐hour glucose [mmol/L]: diagnostic criteria."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 13 2‐hour glucose [mmol/L]: diagnostic criteria. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.1 WHO criteria</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>51</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.92 [‐2.38, 0.55]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.2 Other criteria</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>41</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [‐0.95, 0.95]</p> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD012151-fig-0001"> <img data-id="CD012151-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-AFig-FIG01.png" alt="Trial flow diagram."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-AFig-FIG01.png?filename=nCD012151-AFig-FIG01.ppt&amp;title=1&amp;caption=Trial%20flow%20diagram.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-0002"><img data-id="CD012151-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-AFig-FIG02.png" alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-fig-0002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-AFig-FIG02.png?filename=nCD012151-AFig-FIG02.ppt&amp;title=2&amp;caption=Risk%20of%20bias%20graph%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20presented%20as%20percentages%20across%20all%20included%20trials%20%28blank%20cells%20indicate%20that%20the%20particular%20outcome%20was%20not%20measured%20in%20some%20trials%29.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-AFig-FIG02.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-0003"><img data-id="CD012151-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-AFig-FIG03.png" alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the trial did not measure that particular outcome)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the trial did not measure that particular outcome). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-fig-0003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-AFig-FIG03.png?filename=nCD012151-AFig-FIG03.ppt&amp;title=3&amp;caption=Risk%20of%20bias%20summary%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20for%20each%20included%20trial%20%28blank%20cells%20indicate%20that%20the%20trial%20did%20not%20measure%20that%20particular%20outcome%29.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-AFig-FIG03.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00101"><img data-id="CD012151-fig-00101" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-01.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 1 Incidence of type 2 diabetes."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 1 Incidence of type 2 diabetes. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-01.png?filename=nCD012151-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%201%20Incidence%20of%20type%202%20diabetes.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00102"><img data-id="CD012151-fig-00102" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-02.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 2 Mild hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 2 Mild hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00102" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-02.png?filename=nCD012151-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%202%20Mild%20hypoglycaemia.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00103"><img data-id="CD012151-fig-00103" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-03.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 3 Severe hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 3 Severe hypoglycaemia.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00103" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-03.png?filename=nCD012151-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%203%20Severe%20hypoglycaemia.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00104"><img data-id="CD012151-fig-00104" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-04.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 4 Fasting blood glucose control."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 4 Fasting blood glucose control. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00104" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-04.png?filename=nCD012151-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%204%20Fasting%20blood%20glucose%20control.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00105"><img data-id="CD012151-fig-00105" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-05.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 5 Fasting blood glucose control: type of SU."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 5 Fasting blood glucose control: type of SU. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00105" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-05.png?filename=nCD012151-CMP-001-05.ppt&amp;title=1.5&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%205%20Fasting%20blood%20glucose%20control%3A%20type%20of%20SU.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00106"><img data-id="CD012151-fig-00106" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-06.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 6 Fasting blood glucose control: duration of intervention."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 6 Fasting blood glucose control: duration of intervention. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00106" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-06.png?filename=nCD012151-CMP-001-06.ppt&amp;title=1.6&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%206%20Fasting%20blood%20glucose%20control%3A%20duration%20of%20intervention.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00107"><img data-id="CD012151-fig-00107" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-07.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 7 Fasting blood glucose control: diagnostic criteria."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 7 Fasting blood glucose control: diagnostic criteria. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00107" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-07.png?filename=nCD012151-CMP-001-07.ppt&amp;title=1.7&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%207%20Fasting%20blood%20glucose%20control%3A%20diagnostic%20criteria.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00108"><img data-id="CD012151-fig-00108" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-08.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 8 Fasting blood glucose control: age."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 8 Fasting blood glucose control: age. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00108" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-08.png?filename=nCD012151-CMP-001-08.ppt&amp;title=1.8&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%208%20Fasting%20blood%20glucose%20control%3A%20age.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-08.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00109"><img data-id="CD012151-fig-00109" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-09.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 9 Extension period: fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 9 Extension period: fasting blood glucose. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00109" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-09.png?filename=nCD012151-CMP-001-09.ppt&amp;title=1.9&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%209%20Extension%20period%3A%20fasting%20blood%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-09.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00110"><img data-id="CD012151-fig-00110" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-10.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 10 2‐hour glucose [mmol/L]."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 10 2‐hour glucose [mmol/L].</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00110" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-10.png?filename=nCD012151-CMP-001-10.ppt&amp;title=1.10&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%2010%202%E2%80%90hour%20glucose%20%5Bmmol%2FL%5D.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-10.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00111"><img data-id="CD012151-fig-00111" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-11.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 11 2‐hour glucose [mmol/L]: type of SU."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 11 2‐hour glucose [mmol/L]: type of SU. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00111" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-11.png?filename=nCD012151-CMP-001-11.ppt&amp;title=1.11&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%2011%202%E2%80%90hour%20glucose%20%5Bmmol%2FL%5D%3A%20type%20of%20SU.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-11.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00112"><img data-id="CD012151-fig-00112" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-12.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 12 2‐hour glucose [mmol/L]: duration of intervention."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 12 2‐hour glucose [mmol/L]: duration of intervention. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00112" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-12.png?filename=nCD012151-CMP-001-12.ppt&amp;title=1.12&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%2012%202%E2%80%90hour%20glucose%20%5Bmmol%2FL%5D%3A%20duration%20of%20intervention.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-12.png">Open in new tab</a></div> </div> <div class="figure" id="CD012151-fig-00113"><img data-id="CD012151-fig-00113" src="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-13.png" alt="Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 13 2‐hour glucose [mmol/L]: diagnostic criteria."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Sulphonylureas as monotherapy vs placebo, Outcome 13 2‐hour glucose [mmol/L]: diagnostic criteria. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-fig-00113" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/ppt/CDSR/CD012151/image_n/nCD012151-CMP-001-13.png?filename=nCD012151-CMP-001-13.ppt&amp;title=1.13&amp;caption=Comparison%201%20Sulphonylureas%20as%20monotherapy%20vs%20placebo%2C%20Outcome%2013%202%E2%80%90hour%20glucose%20%5Bmmol%2FL%5D%3A%20diagnostic%20criteria.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016, 10. Art. No.: CD012151. DOI: http://dx.doi.org/10.1002/14651858.CD012151.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012151.pub2/media/CDSR/CD012151/image_n/nCD012151-CMP-001-13.png">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD012151-tbl-0001" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Summary of findings (sulphonylureas)</span></div> <tbody> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at risk for the development of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people at risk for the development of type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> sulphonylureas (data available for glimepiride only) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>No of participants<br> (trials)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Glimepiride</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: mean 3.7 years</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>274<br> (1) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>very low</b><sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5/136 (3.7%) participants in the glimepiride group versus 2/138 (1.4%) in the placebo group </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Incidence of type 2 diabetes mellitus</b> </p> <p>Measured as 2 consecutive fasting blood glucose values ≥ 6.1 mmol/L (<a href="./references#CD012151-bbs2-0002">NANSY 2011</a><sup>b</sup>) or no definition provided (<a href="./references#CD012151-bbs2-0001">Eriksson 2006</a>)<br> Follow‐up: 6 months and a mean of 3.7 years </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>361 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>271 per 1000</b> (195 to 376) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.75</b> (0.54 to 1.04) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>307<br> (2) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>very low</b><sup>c</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Serious adverse events</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: mean 3.7 years</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>274<br> (1) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>very low</b><sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1/136 (0.7%) participants died due to cardiovascular disease in the sulphonylurea monotherapy group and 2/138 (1.4%) participants died in the placebo group </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Non‐fatal myocardial infarction, non‐fatal stroke, congestive heart failure</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>Assumed risk was derived from the event rates in the comparator groups<br> <sup>a</sup>Downgraded by three levels because of serious imprecision and possible publication bias<br> <sup>b</sup>Diagnostic criterion for trial entry was impaired fasting glucose in the NANSY trial (baseline glycosylated haemoglobin A1c was 4.9% for both groups) and impaired glucose tolerance in Eriksson 2006. In the NANSY trial participants took glimepiride on the days when glycaemic variables were measured<br> <sup>c</sup>Downgraded by three levels because of indirectness, serious imprecision and possible publication bias. Trial sequential analysis showed that only 4.5% of the diversity‐adjusted information size was accrued so far to detect or reject a 10% relative risk reduction </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Summary of findings (sulphonylureas)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD012151-tbl-0002" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">Summary of findings (meglitinide analogues)</span></div> <tbody> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at risk for the development of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people at risk for the development of type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> meglitinide analogues (nateglinide) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Nateglinide</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>No of participants<br> (trials)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: median 6.5 years</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9306 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>310/4645 (6.7%) participants died in the nateglinide group versus 312/4661 (6.7%) participants in the placebo group. Vital status was available for 95.7% of participants at the end of follow‐up. The HR was 1.00; 95% CI 0.85 to 1.17; P = 0.98 </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Incidence of type 2 diabetes mellitus</b> </p> <p>Defined as: fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) or a 2‐hour blood glucose after a glucose‐load test ≥ 11.1 mmol/L (200 mg/dL) or by an adjudication committee<sup>b</sup> </p> <p>Follow‐up: median 5 years</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9306 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Type 2 diabetes mellitus developed in 1674/4645 (36.0%) participants in the nateglinide group and in 1580/4661 (33.9%) in the placebo group. The HR was 1.07; 95% CI 1.00 to 1.15; P = 0.05 </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: median 5 years</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9306 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The number of participants who experienced a serious adverse events was 2066/4602 (44.9%) participants in the nateglinide group versus 2089/4599 (45.6%) participants in the placebo group </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: 6.5 years</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9306 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The number of participants who died due to cardiovascular disease was 126/4645 (2.7%) participants in the nateglinide group versus 118/4661 (2.5%) participants in the placebo group. The HR was 1.07; 95% CI 0.83 to 1.38; P = 0.60 </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>(a) Non‐fatal myocardial infarction</b> </p> <p><b>(b) Non‐fatal stroke</b> </p> <p><b>(c) Congestive heart failure</b> </p> <p>Follow‐up: median 6.3 years</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9306 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>(a), (b), (c):</p> <p>⊕⊕⊕⊝<br> <b>moderate</b><sup>a</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>(a) The number of participants who experienced a non‐fatal myocardial infarction during the trial was 116/4645 (2.5%) participants in the nateglinide group versus 122/4661 (2.6%) participants in the placebo group </p> <p>(b) The number of participants who experienced a non‐fatal stroke during the trial was 100/4645 (2.2%) participants in the nateglinide group versus 110/4661 (2.4%) participants in the placebo group </p> <p>(c) The number of participants developing congestive heart failure was not reported. However, the number of participants hospitalised for congestive heart failure was 85/4645 (1.8%) participants in the nateglinide group versus 100/4661 (2.1%) participants in the placebo group. The HR was 0.85; 95% CI 0.64 to 1.14; P = 0.27 </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9306 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>One trial specified the assessment of health economics (NAVIGATOR 2010). However, trial authors did not provide data </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level because of imprecision, high risk of selective reporting and possible publication bias (see <a href="./appendices#CD012151-sec2-0033">Appendix 18</a>)<br> <sup>b</sup>Diagnostic criterion for the NAVIGATOR trial entry was impaired glucose tolerance; baseline glycosylated haemoglobin A1c was 5.8% for both groups. Progression to diabetes was confirmed by laboratory measurements in 1587 participants in the nateglinide group (34.2%) and 1495 participants in the placebo group (32.1%). Progression to diabetes was determined by the adjudication committee in the case of 87 participants assigned to nateglinide (1.9%) and 85 assigned to placebo (1.8%) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">Summary of findings (meglitinide analogues)</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-tbl-0002" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD012151-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description of power and sample size calculation</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Screened/eligible<br> (N)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Randomised<br> (N)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ITT<br> (N)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Analysed<br> (N)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Finishing trial<br> (N)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Randomised finishing trial<br> (%)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Follow‐up<br> (extended follow‐up)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Eriksson 2006</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: glipizide 2.5 mg</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p><sup>b</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><sup>‐c</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>6 months (18 months)</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐<sup>c</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>37</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>32</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>NANSY 2011</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: glimepiride 1.0 mg</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Quote: "...assuming 3% conversion rate per year and 33% reduction of diabetes development with 5% significance and 80% statistical power" </p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>136</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>136</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐<sup>e</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>5 years or until diabetes developed, average follow‐up period 3.7 years</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>138</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>138</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐<sup>e</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>288<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>274</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>274</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>203</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>74.1</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>NAVIGATOR 2010</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: nateglinide 60 mg, three times daily</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Quote: "The sample size calculation was therefore based on a 'subadditivity / 75% additivity of effects' approach, assuming an effect size of 32% on cardiovascular outcome of the two drugs in combination. The treatment discontinuation rate was assumed to be 30% over five years, corresponding to approximately 6.9% per annum. While patients on treatment were assumed to have the full effect (i.e. 20% reduction of hazard rate if in the monotherapy group), it was assumed that patients who discontinued treatment would have only ¼ of the treatment effect remaining as carry‐over effect. Furthermore, it was expected that 75% of the patients who discontinued treatment could be followed up for events. The remaining 25% would comprise patients completely lost to follow‐up, patients who die (without reaching a primary endpoint), and those for whom events are unintentionally not reported by the investigator. Based on these assumptions, a total of 9152 patients will provide 90% testwise power to detect a treatment difference in the extended cardiovascular endpoint" </p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>43 502</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4748</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4645</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4645</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3726</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78.5</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>Quote: "The median follow‐up time for data on vital status was 6.5 years, and the median follow‐up times for data on the diabetes, extended cardiovascular, and core cardiovascular outcomes were 5.0, 6.3, and 6.4 years, respectively"<sup>f</sup> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4770</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4661</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4661</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3747</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78.6</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9518</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9306</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9306</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7473</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78.5</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Osei 2004</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: GITS 5 mg</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>24 months (26 months)</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>9</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="4" bgcolor="#ffffff"> <p><b>Page 1993</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: gliclazide 40 mg twice daily</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="" valign="top" colspan="1" rowspan="4" bgcolor="#ffffff"> <p>6 months (7 months)</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C1: placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>87.5</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C2: diet + exercise</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>23</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78.2</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>37</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>31</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>31</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>31</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>83.8</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="5" bgcolor="#ffffff"> <p><b>Papoz 1978</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I1: glibenclamide 2.0 mg twice daily + metformin 850 mg twice daily</p> </td> <td align="" valign="top" colspan="1" rowspan="4" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="4" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>29</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>75.9</p> </td> <td align="" valign="top" colspan="1" rowspan="5" bgcolor="#ffffff"> <p>2 years (2 years)</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I2: glibenclamide 2.0 mg twice daily + placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>28</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>22</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>78.6</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C1: placebo + metformin 850 mg twice daily</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>23</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>23</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>23</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>76.7</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C2: placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>19</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>57.6</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>120</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>71.7</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b><i>Grand total</i> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>All interventions<sup>h</sup> </i> </b> </p> </td> <td align="" valign="top" colspan="2" rowspan="3" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>4820</i> </b> </p> </td> <td align="" valign="top" colspan="2" rowspan="3" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>3792</i> </b> </p> </td> <td align="" valign="top" colspan="2" rowspan="3" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>All comparators<sup>h</sup> </i> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>4873</i> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>3830</i> </b> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>All interventions and comparators<sup>i</sup> </i> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>10,018</i> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>7825 <sup>j</sup> </i> </b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>‐ denotes not reported</p> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial or, if not available, duration of intervention; extended follow‐up refers to follow‐up of participants once the original study was terminated as specified in the power calculation<br> <sup>b</sup>Particpants identified through screening of another trial (<a href="./references#CD012151-bbs2-0043">Botnia Study 1996</a>). Quote: "The subjects included in the present study represented the first consecutive 37 subjects who maintained their IGT status on repeated OGTT testing during 1 year"<br> <sup>c</sup>The investigators described that they randomised 37 participants, and three dropped out shortly after. However, they do not describe how these three participants were allocated, but only describe that after the three participants had left 17 were allocated to each intervention group<br> <sup>d</sup>The investigators described that 14 randomised participants withdrew before the first occasion to establish the conversion to type 2 diabetes mellitus. All except one dropped out for administrative reasons. However, it was not specified to which intervention group these participants were allocated<br> <sup>e</sup>71 individuals interrupted participation prematurely, however it was not described to which groups they belonged<br> <sup>f</sup>The trial was predefined to stop and the final analysis performed when 1374 participants have had an adjudication committee confirmed extended cardiovascular endpoint<br> <sup>h</sup>Not all trials described the number of participants randomised to each intervention group<br> <sup>i</sup>Two trials did not report the number of randomised participants per intervention group. Therefore, numbers do not add up accurately<br> <sup>j</sup>Not all trials reported the number of participants finishing the trial </p> <p>C: comparator; GITS: glipizide gastrointestinal therapeutic system; I: intervention; ITT: intention‐to‐treat; NANSY: The Nepi ANtidiabetes StudY </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/full#CD012151-tbl-0004" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD012151-tbl-0003" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Sulphonylureas as monotherapy vs placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of type 2 diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>307</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.75 [0.54, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Mild hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Fasting blood glucose control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 [‐0.59, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Fasting blood glucose control: type of SU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 [‐0.59, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 Second‐generation SU</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>87</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.27 [‐0.57, 0.02]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 Third‐generation SU</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.70 [‐1.72, 0.32]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 Fasting blood glucose control: duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 [‐0.59, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.1 duration less than 2 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>46</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.28 [‐0.95, 0.39]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6.2 duration 2 years or more</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>59</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.35 [‐0.69, 0.00]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Fasting blood glucose control: diagnostic criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.31 [‐0.59, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.1 WHO diagnostic</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>51</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.22 [‐0.86, 0.42]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7.2 Other criteria</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>54</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.36 [‐0.70, ‐0.02]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">8 Fasting blood glucose control: age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>105</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.48 [‐0.79, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.1 age less than 50 yrs</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>72</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.62 [‐0.95, ‐0.30]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8.2 age above 50 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [‐0.60, 0.60]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">9 Extension period: fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>45</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.08 [‐1.04, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">10 2‐hour glucose [mmol/L] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>92</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.42 [‐1.28, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">11 2‐hour glucose [mmol/L]: type of SU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>92</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.42 [‐1.28, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.1 Second‐generation SU</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>74</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.16 [‐0.90, 0.57]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>11.2 Third‐generation SU</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>18</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐2.0 [‐4.20, 0.20]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">12 2‐hour glucose [mmol/L]: duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>92</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.42 [‐1.28, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.1 Duration 2 years or more</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>59</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.75 [‐2.64, 1.15]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>12.2 Duration less than 2 years</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.40 [‐1.56, 0.76]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">13 2‐hour glucose [mmol/L]: diagnostic criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>92</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.42 [‐1.28, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.1 WHO criteria</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>51</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.92 [‐2.38, 0.55]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>13.2 Other criteria</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>41</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [‐0.95, 0.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Sulphonylureas as monotherapy vs placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012151.pub2/references#CD012151-tbl-0003" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012151-note-1207">Español</a> </li> <li class="section-language"> <a class="" href="hr#CD012151-note-1206">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD012151-note-1204">Русский</a> </li> <li class="section-language"> <a class="" href="zh#CD012151-note-1205">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1581423095000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581423095000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717691000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717708000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717777000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717709000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581717714000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x2526cookiesEnabled\x26templateType\x3dreferences\x26cookiesEnabled\x3d\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012151\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x2526cookiesEnabled"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x2526cookiesEnabled\x26templateType\x3dreferences\x26cookiesEnabled\x3d\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012151\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x2526cookiesEnabled\x26templateType\x3dreferences\x26cookiesEnabled\x3d\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012151\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x2526cookiesEnabled\x26templateType\x3dreferences\x26cookiesEnabled\x3d\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012151\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012151\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581423095000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=dMP9BDfH&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_cookiesEnabled=&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012151.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012151.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">

<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD012151.pub2/references/en?cookiesEnabled" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD012151.pub2/references/es?cookiesEnabled" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012151.pub2%2Freferences%3FcookiesEnabled" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583241780377" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x2f;references&#x3f;cookiesEnabled" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583241780380" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012151&#x2e;pub2&#x2f;references&#x3f;cookiesEnabled" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD012151.pub2";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 